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Abstract

TOBRAMYCIN DISPOSITION IN THE LUNG FOLLOWING AIRWAY
ADMINISTRATION
By Min Li, M.S.

A dissertation submitted in partially fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Director: Peter R. Byron, Ph.D.
Professor and Chairman
Department of Pharmaceutics, School of Pharmacy

Tobramycin disposition following airway administration was evaluated by meta-analysis of
human data in the literature and, experimentally, using a realistic ex vivo model, the isolated
perfused rat lung preparation (IPRL). Pulmonary bioavailability of inhaled tobramycin in
published studies was re-evaluated separately for CF and healthy adults, with the drug’s intrinsic
pharmacokinetic (PK) parameters obtained from intravenous (IV) studies in the literature. While

large variations in tobramycin’s clearance precluded accurate assessment of its bioavailability, the
results were indicative of substantial pulmonary absorption, in spite of its hydrophilic and poly
cationic properties. To explore its disposition kinetics and mechanisms following airway
administration, tobramycin absorption was investigated as a function of dose in the IPRL. The
cumulative fraction of the administered tobramycin dose reaching the perfusate versus time, was
bi-exponential and dose-dependent, unlike that of the marker solutes fluorescein and mannitol,
both of which showed first-order and dose-independent kinetics. A kinetic model that incorporated
lung tissue binding (or sequestration) alongside passive absorption was employed successfully to
describe the aminoglycoside’s disposition in the IPRL following airway administration.
Tobramycin’s absorption was fast with the first-order absorption rate constants (0.065-0.070 min1

) close to those seen with fluorescein (0.076 min-1), but a dose-, and concentration-dependent slow

onset tissue binding prolonged its presence in the rat lung. Binding was confirmed by independent
dynamic dialysis experiments using sliced lung prepared from the intact IPRL, immediately
following airway administration using an identical technique as that used in tobramycin absorption
studies. Dosing solution osmolality and pH had negligible effects on the drug’s disposition in the
IPRL, when these were investigated over experimental ranges that could be used clinically. While
tobramycin itself was found to accelerate mannitol’s absorption, and thus affect airway epithelial
integrity when administered at high doses, the effect was undetectable at a dose level in rat lungs
that was believed to produce airway concentrations corresponding to those in human patients using
TOBI®. These findings may partly explain the apparent success of inhaled tobramycin therapy in
the treatment of pulmonary infections.

Chapter I
BACKGROUND AND SIGNIFICANCE

Tobramycin administration direct to the airways via nebulizer has brought great improvements
to the health and wellbeing of cystic fibrosis (CF) patients and others suffering from chronic
pulmonary infections with pathogens such as Pseudomonas aeruginosa (Chuchalin et al., 2009).
The topical administration of this class of antibiotics by inhalation offers an attractive alternative,
delivering high concentrations of drug directly to the site of infection while minimizing the risk of
toxicities associated with high systemic exposure (Geller et al., 2002; Touw et al., 1995). Although
the efficacy and safety of inhaled tobramycin is well-recognized in clinical circles, its absorption
and disposition following airway administration has not been thoroughly studied in humans and
animals, and it remains possible that its pulmonary disposition influences its efficacy.

Historically, tobramycin has been administered parenterally for treatment of lung infections
with limited success; serum to lung drug concentration ratios of 10:1 are typical (Moriarty et al.,
2007), meaning that high serum concentrations are required to get sufficient drug into the airways
and these often caused toxicity (Selimoglu, 2007; Todd and Hottendorf, 1995). These observations,
taken with tobramycin’s extremely poor oral bioavailability (Jaresko and Alexander, 1995; Phillips
and Shannon, 1997), all appear to be associated with the low permeability of epithelia to this
hydrophilic drug. Tobramycin’s biopharmaceutical properties may be further complicated by the
drug’s tendency to accumulate in or on certain epithelial cells, e.g. in the kidney or inner ear
1

(Mingeot-Leclercq and Tulkens, 1999; Selimoglu, 2007). Clearly, topical administration of
tobramycin by nebulizer has the advantage that high concentrations may be targeted to the airways
where its antimicrobial effect is believed to be concentration-dependent and its efficacy is related
to the magnitude of the airway Cmax (the peak level of drug concentration in the airways) to MIC
(minimum inhibitory concentration) ratio (MacArthur et al., 1984). However, the ideal duration
over which concentration should be maintained in the airways of infected patients is unknown.

In general, tobramycin bioavailability from the lung following inhalation is therefore presumed
to be slow and incomplete, in favor of sustaining its local antimicrobial activities in the airways,
due to its hydrophilicity and polycationic properties at physiologic pH (Pai and Nahata, 2001; Poli
et al., 2007). However, tobramycin studies in the lung following inhalation are quite limited, and
there is insufficient published scientific evidence to support this theory. In the study of Cooney et
al., mean absolute bioavailability (±SD) in 6 CF adults was estimated to be 9.1 (±3.8) %, based on
the ratios of AUC (area under drug serum concentration versus time curve) normalized by dose
(Cooney et al., 1994). In this case, the data was normalized based on the “emitted dose” from the
nebulizer (Microstate Ultra Nebulizer was used for inhalation) compared to the intravenous (IV)
dose as the reference; notably, however, the true lung dose was not determined. Tobramycin
pulmonary bioavailability was also assessed using a population pharmacokinetic approach for
multiple doses (twice daily for 28 days) of TOBI® (300 mg in 5 mL 0.25 normal saline; Chiron
Corporation; Seattle, WA) administered via a jet nebulizer (PARI LC; Pari Respiratory; Richmond,
VA) in a phase III clinical trial in which 258 CF patients were enrolled (Geller et al., 2002). In that
study, the bioavailability of inhaled tobramycin was reported as 11.7 %, calculated using the
“population estimate of the apparent clearance” (CL/F= 49.6 L/h) with an average value for
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systemic clearance, CL of 5.79 L/h from 3 published IV studies (Geller et al., 2002). Geller’s result
was comparable with that from Touw et al. (1997), given the large inter-patient variations in both
studies; Touw et al. estimated bioavailability at 17.5% based on the urinary output of 6 CF adults
after a single dose of 600 mg tobramycin via an ultrasonic nebulizer (WISTO SENIOR; Wisto,
Woerden, Netherlands) (Touw et al., 1997).

Notably, the fractions of the administered doses depositing in the lung immediately following
tobramycin inhalation were determined in none of the studies described above. Therefore, values
for pulmonary bioavailability were calculated based on the nominal doses loaded in the nebulizer
or the emitted doses believed to be delivered from them. Due to the generally inefficient lung
delivery of nebulizer devices, large drug losses are expected during drug administration and only
a small dose fraction can reach the capillary-perfused regions for absorption into the systemic
circulation (Coates et al., 2000; Touw et al., 1995). The fraction of each administered dose
eventually deposited in the lung depends on the device, formulation and the airways geometry and
breath patterns of users; the average percentage of loaded dose is expected to range between 5 and
15% for the ultrasonic and jet nebulizers used in these studies (Ilowite et al., 1987; Lenney et al.,
2011; Touw et al., 1997). In this scenario therefore, although tobramycin pulmonary
bioavailability was stated to be low (Cooney et al., 1994; Geller et al., 2002), the results indicate
that the systemically available fractions of the total lung doses (mass deposited in the lung region)
delivered by nebulizer may actually approach 1, in spite of the drug’s ionization and hydrophilicity.

In the study of Cooney et al., the absorption rate was also assessed after calculating the
cumulative fraction of drug absorbed as function of time using the Loo-Riegelman method
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(Cooney et al., 1994). The mean absorption time estimated for the 6 subjects ranged from 0.25 to
1.5 hours. Due to the small number of subjects and large inter-subject variability seen in this study,
the reliability of this result is debatable. In the study of Touw et al., the first-order absorption rate
constant (ka) for tobramycin after inhalation was estimated using compartmental pharmacokinetic
(PK) analysis; values were reported in the range of 0.56-4.16 hr-1 with wide inter-subject variations
(Touw et al., 1997), while the terminal t1/2, which referred to the half life of the terminal phase of
drug serum concentration time profiles, ranged from 8.9 to 19.3 hours (Touw et al., 1997). In this
study, this prolonged terminal t1/2, compared to those observed typically in IV studies in the range
of 1.5 to 3 hours (Levy et al., 1984; Touw et al., 1993; Town et al., 1996), was interpreted to be
due to the phenomenon of “flip-flop” that implied a delayed absorption from a depot of tobramycin
in the lung. Similarly, the prolonged terminal t1/2 (about 8 hours) following inhalation was also
observed in another study conducted by Conte et al. in healthy volunteers (Conte et al., 1993).
While these prolonged serum half-lives have been observed, the values are not consistent with
those for absorption from Cooney et al.(1994); nor has the phenomenon been seen in other studies
with similar designs (Geller et al., 2002; Newhouse et al., 2003; Pilcer et al., 2008; Poli et al.,
2007). The discrepancies may be attributed to differences in study designs, sampling duration and
frequencies, PK analysis methods, accuracy, precision and LLOQ (lower limit of quantification)
of assay methods, as well as variations between subjects, studies, and dosing regimens. Overall
however, the reports emphasize our poor understanding of pulmonary absorption and disposition.

Despite this controversy, tobramycin is believed to exit the lung slowly following inhalation.
This theory may be derived from the persistence of high tobramycin concentration in airway
secretions following inhalation in animals and humans (Eisenberg et al., 1997; Gibson et al., 2003;
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Lenoir et al., 2007; Valcke and Pauwels, 1991). Evidence of high alveolar lining fluid (ALF)
concentrations that persisted for as long as 6 hours and remained far in excess of the MIC
(minimum inhibitory concentration) of susceptible respiratory pathogens was shown in rats
following endotracheal administration (Valcke and Pauwels, 1991). In humans, potential
tobramycin accumulation in respiratory secretions with repeated dosing TOBI (300 mg b.i.d.) in
young CF patients (≤6 years old) was also observed (Gibson et al., 2003), although a short half life
of drug disappearance from sputum was generally found after single dose administration (Geller
et al., 2003; Weber et al., 1994). Tobramycin persistence in ALF of pneumonia patients collected
by bronchoalveolar lavage (BAL) was also shown in a clinical trial after IV administration, in
which a slower rate of drug disappearance occurred from ALF than from serum (Carcas et al.,
1999) was thought to indicate that the ALF constituted a deep compartment for tobramycin.
Moreover, in vitro studies also found that tobramycin bound to sputum and that binding appeared
saturable (Mendelman et al., 1985). In spite of these results, however, tobramycin binding or
sequestration in the lung and the extent to which binding actually affects the drug’s disposition
following inhalation has not been studied.

While the sites and mechanisms of drug binding or sequestration in lung tissue remain to be
investigated, the drug’s multiple positive charges and the presence of “ubiquitous negative charges
on the surface of cell membranes” has been mentioned as one type of possible interaction in the
airways (Patton et al., 2004). The hypothesis was inferred partly from results of the studies of
aminoglycosides’ nephrotoxicity, in which the drugs were believed to initially bind to acidic
phospholipids in the brush-border membrane of proximal tubule cells and then cause accumulation
of this class of drugs in the epithelial cells of renal proximal tubules (Nagai and Takano, 2004).
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Notably, aminoglycosides’ binding to proximal tubule and inner ear cells has been investigated for
the studies of aminoglycoside nephrotoxicity and ototoxicity. Since there are the similarities in
composition and structure (phospholipid bilayers) among epithelial membranes, the binding of
aminoglycosides to other epithelia, especially to the lung, appears to merit further investigation.

In summary, the extent and rate of tobramycin absorption, the existence of tissue binding and/or
lung retention remains uncertain, especially from the kinetic and mechanistic aspects, in part
because of the difficulties of studying pulmonary disposition in animals and humans. Since a
solute’s physicochemical properties affect its penetration through the pulmonary barrier (Patton et
al., 2004), an understanding of tobramycin’s molecular characteristics is important. Tobramycin
is an aminoglycoside with a relatively large molecular weight (MW=467.5 Da). The structure of
this compound (Figure I.1) consists of an aminocyclitol connected to two amino sugars by
glycosidic bonds. There are 5 amino groups in the structure and the pKas shown in Figure I.1 are
as reported by Szilagj et al.(1993); these amino groups will be predominately ionized and the drug
should carry about 2.5-3 positive charges based on the reported pKa values under physiological
conditions (pH7.4). The predicted LogP (logarithm of the partition coefficient between octanol
and water for the neutral form) and LogD (pH 7.4) (logarithm of the distribution coefficient
between octanol and water at pH7.4) were reported to be -4.224 and -9.54, respectively, indicating
the drug’s extreme hydrophilicity and how this is enhanced by protonation of the amino groups
(LogP and LogD prediction were performed by ACD/PhysChem Suite (Advanced Chemistry
Development, Inc., Toronto, Canada), a software used for prediction of physicochemical
properties).

6

pKa 7.8

pKa 8.9
pKa 7.1

pKa 5.7

pKa 8.3
Figure I.1 Tobramycin chemical structure and pKa values

Solute absorption from the airways of the lung is generally believed to occur via diffusion
and/or partitioning (Brown and Schanker, 1983). For hydrophilic solutes, passive diffusion is
expected via paracellular tight junctions between epithelial cells as the primary pathway through
pulmonary barrier, due to the difficulties that such solutes experience in penetrating into the
phospholipid bilayers in epithelial cell membranes (Brown and Schanker, 1983; Effros and Mason,
1983; Schanker and Less, 1977; Schneeberger, 1991). The absorption of lipophilic solutes, to the
contrary, occurs by transcellular diffusion/partition, and correlates with molecular partition
coefficients between octanol and water (Brown and Schanker, 1983). The absorption of lipophilic
compounds is generally faster than that of hydrophilic ones, given a similar range of molecular
size (Brown and Schanker, 1983), since the surface area of the epithelial cell membranes in the
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lung, available for transcellular diffusion, is much larger than that for intercellular or paracellular
diffusion via tight junctions between cells.

Tight junctions are known as a complex belt-like network of strands and fibrils which are
polymers of interacting transmembrane proteins and lipids (Su and Sheppard, 2008); they are
believed to represent relatively impermeable structures in which “aqueous pores” reside (Sakagami,
2000). These pores may alternate between open and closed configurations as channels for solute
transport (Claude, 1978; Reuss et al., 1991). These hypothetical “pores” with various sizes in the
pulmonary epithelium were demonstrated in several studies by Schanker and coworkers (Enna and
Schanker, 1972; Lin and Schanker, 1983; Schanker and Hemberger, 1983). In those studies, the in
vivo disappearance rates of miscellaneous hydrophilic compounds from the lungs were determined
by quantifying the dose remaining in the lungs at various time points following intra-tracheal
instillation or aerosol inhalation in anesthetized animals (Brown and Schanker, 1983; Enna and
Schanker, 1972). Notably, the absorption of a series of non-metabolized and lipid-insoluble
saccharides, with similarities to aminoglycosides in structure and metabolic properties (nonmetabolized in lung), were also investigated by Schanker’s group (Enna and Schanker, 1972). The
absorption of these saccharides appeared to be dose-independent with the first-order absorption
rate constants, ka, ranging from 0.025-10.4 h-1 and where ka values were inversely related to
molecular weight. The mean absorption half life of mannitol (MW=182 Da), sucrose (MW=342
Da) and inulin (MW=5,250 Da) in rat lungs were reported to be 65, 87, and 225 minutes
respectively. In their study, passive paracellular diffusion (via tight junctions) was concluded as
the pathway for these saccharides’ absorption from the airways into the blood, because both the
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extent and rate constants for absorption were dose- and concentration-independent (Enna and
Schanker, 1972).

Clearly, mechanisms other than diffusion and partitioning, such as transporter-mediated
absorption or vesicle-mediated endocytosis and transcytosis, may be involved in solute absorption
from the airways (Patton et al., 2004). In a recent review of drug transporters in the lung, the
expression and potential impact of transporters (such as P-glycoprotein, P-gp, and organic cation
and organic anion transporters, OCT and OAT, etc.) were described in detail (Bosquillon, 2010).
At this time however, there is no strong evidence to indicate the involvement of transporters in the
absorption of drugs delivered to the lung (Bosquillon, 2010). Similarly, our knowledge of
pulmonary absorption by vesicle mediated endocytosis and transcytosis is limited and mostly
associated with macromolecules (Patton, 1996).

In general, solute disposition in the lung following inhalation is a complex function of regional
deposition, mucociliary clearance, active and/or passive absorption, tissue sequestration and
metabolism (Byron et al., 1994; Niven et al., 1990). Unfortunately, the kinetics and mechanisms
describing the behavior of individual solutes remain largely theoretical, due to the lack of
appropriate experimental systems for characterization of these processes. In vivo studies in animals,
combined with intratracheal instillation or aerosol administration, have been applied to
characterize solute absorption rate and extent following airway administration in Schanker and
others’ laboratories (Brown and Schanker, 1983; Sakagami et al., 2003). While such methods
enable the direct assessment of drug pharmacokinetics in vivo, reproducible airway dosing and
considerable animal sacrifice are necessary (large numbers are required) to reduce the inter-animal
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variations in whole body clearance that make characterization of absorption and disposition
possible (Sakagami, 2006).

More recently, reconstructed lung epithelium, cultured from human lung adenocarcinoma cell
lines or primary cultured alveolar epithelial cells, have been used to clarify the kinetics and
mechanisms of solute transepithelial transport in vitro (Sakagami, 2006). The convenience and
low cost of cell culture are potentially great advantages, when these methods are compared to the
use of whole animals. Unfortunately, the variables associated with lung cell isolation and culture
and a lack of standardization create uncertainties so that results between laboratories from similarly
cultured cells are rarely comparable (Sakagami, 2006). Moreover, the relevance of using these
reconstructed barriers to represent complex intact lung is still debatable. For these reasons, the ex
vivo model of the isolated perfused lung appears to resolve some deficiencies in both these in vivo
and in vitro methods; it also offers a great alternative for the study of lung-specific
pharmacokinetics, by virtue of its well-maintained structural and functional integrity and the
absence of the whole body complication introduced by solute distribution and elimination in vivo
(Sakagami, 2006). The ex vivo method provides advantages, such as enabling relatively accurate
and reproducible drug administration to the airways, convenient sampling of perfusate and lavage
fluids, and easy determination of mass balance (Tronde et al., 2003). Hence, this model has found
use for investigations of absorption, tissue sequestration, metabolism and mucociliary clearance.
The isolated perfused rat lung (IPRL) preparation described by Byron and Niven, that combined
with a highly reproducible “forced intratracheal instillation” technique for solute administration
into the airways, brought great improvements to the accurate and precise determination of
absorption rate and extent (Byron and Niven, 1988; Byron et al., 1986). In part because the IPRL
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preparation is studied in a physiological normal orientation (horizontally suspended) with a
horizontally exteriorized trachea cannula, the preparation has found its way into text books as a
way of studying aerosol deposition (Byron et al., 1986; Sinko, 2006). The method has also been
employed successfully in many studies to address issues regarding the kinetics and mechanisms
of solute absorption and disposition following airway administration in a number of different
academic groups (Byron et al., 1994; Niven and Byron, 1990; Niven et al., 1990; Pang et al., 2005;
Sakagami et al., 2002).

The use of the IPRL preparation for the study of solute binding and/or sequestration after airway
administration is yet to be described. The affinity and capacity of solute tissue binding has largely
been investigated in vitro using equilibrium dialysis with tissue homogenates or slices (Pacifici
and Viani, 1992; Wilkinson et al., 1986). Clearly, structurally modified tissues are unlikely to
behave like intact organs, and therefore results from in vitro equilibrium dialysis experiments fail
to provide usable predictive information for solute tissue binding in vivo. In this thesis, an attempt
has been made to improve the bio-relevance of an in vitro binding assay and to marry the results
to those from the intact organ. The dialysis of sliced isolated lung tissues was performed
immediately after drug administration to the airways, to gain more insight to the in vivo lung tissue
binding of tobramycin by mimicking the environment in which the drug was administered.
Dynamic dialysis under sink conditions was first described by Meyer and Guttman (Meyer and
Guttman, 1968; 1970). The technique was modified in this dissertation to support the use of the
IPRL preparation for the combined characterization of tobramycin’s lung tissue binding behavior
and absorption. This method, initially applied for protein binding studies, has been used
successfully by other groups to study solute-ligand binding, by virtue of its providing more kinetic
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information than equilibrium dialysis alone (Farrell et al., 1971; Hashimoto et al., 1984; Leo et al.,
1999; Meyer and Guttman, 1968; Pedersen et al., 1977).

This dissertation aims to enhance the understanding of pulmonary absorption and retention of
tobramycin in the airways following inhalation by targeting and describing experiments designed
to study the kinetics and mechanisms of absorption and disposition in the lung. In an attempt to
elucidate the kinetics and extent of pulmonary absorption in humans, the systemic bioavailability
of inhaled tobramycin in adults was re-evaluated by performing a meta-analysis of PK studies of
aerosolized tobramycin using the available data in the literature. To explore the kinetics and
mechanisms responsible for aerosolized tobramycin’s pulmonary disposition, the absorption and
binding behavior of tobramycin was then assessed in the most realistic ex vivo model of the rat
lung, the IPRL, as a function of dose and local concentration, using a previously described method
to administer the drug reproducibly (Byron and Niven, 1988). The effect of pH and osmolality of
dosing solutions was also investigated to eliminate possible secondary factors that may impact the
drug’s absorption and disposition. By combining the IPRL preparation with dynamic dialysis, a
disposition model for tobramycin binding and/or sequestration was developed and validated after
drug administration to the airways. Based on the results from these binding experiments, a kinetic
model for tobramycin absorption and disposition following airway administration in the IPRL was
used to interpret and discuss the data from the IPRL. The findings in this study are discussed in
the light of the literature concerning the lung’s interactions with inhaled compounds, perhaps to
aid in the future development of drugs designed to target lung tissue.
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Chapter II
HYPOTHESES AND SPECIFIC AIMS

The efficacy and safety brought about by administration of tobramycin via inhalation is wellrecognized for the treatment of lung infections in clinical circles (Chuchalin et al., 2009). However,
it remains unclear whether the antibiotic’s physicochemical properties are such as to lead to slow
absorption, tissue binding and/or lung retention to sustain the drug’s presence and antimicrobial
properties for periods between dosing. This dissertation was aimed to enhance the understanding
of tobramycin’s absorption from, and retention in, the airways and lung tissues, by targeting
experiments designed to study the kinetics and mechanisms responsible for the drug’s disposition
following airway administration. The central hypothesis was that tobramycin was slowly absorbed
from airways to the blood following local delivery to the lung, primarily by passive diffusion via
the paracellular pathway, due to its hydrophilic and polycationic properties at physiological pH
(Szilagyi et al., 1993). Tobramycin’s bioavailability following airway administration, was
presumed to be low, based on the reportedly poor permeability of aminoglycosides across
gastrointestinal barriers seen following oral administration (Jaresko and Alexander, 1995; Phillips
and Shannon, 1997). Because aminoglycosides and tobramycin have been shown to bind to tissues
in kidney and inner ear to form “deep compartments” (French et al., 1981; Mingeot-Leclercq and
Tulkens, 1999; Nagai and Takano, 2004; Schentag, 1978; Schentag et al., 1978; Stepanyan et al.,
2011), we also hypothesized that the drug could bind to lung tissue and that the degree of this
binding could be dose- and/or concentration-dependent. Because of slow absorption, any retention
13

in the airways was thought likely to prolong the drug’s antimicrobial efficacy following local
delivery. Finally, because these characteristics were believed to be due primarily to the drug’s
physicochemical properties, we hypothesized that the drug’s formulation in dosing solutions with
different osmolalities and small changes in pH were not likely to significantly affect its pulmonary
disposition.

The following Specific Aims were used to test these hypotheses:

1. To estimate tobramycin’s pulmonary bioavailability following inhalation in humans
using pharmacokinetic (PK) meta-analysis. Selected tobramycin blood level and sputum
concentration data from CF and healthy adults were taken from the clinical literature and
re-analyzed using non-compartmental and compartmental approaches to assess
tobramycin’s pulmonary bioavailability. Both the rate and extent of absorption of the lung
deposited dose was assessed. The available sputum PK data following inhalation were also
systematically reviewed and discussed in the light of the earlier meta-analysis of blood
level data. Specific Aim 1 is described in detail in this thesis in Chapter III.

2. To characterize the kinetics and mechanisms of tobramycin’s disposition in the rat
lung following administration to the airways and to build a kinetic model to describe
the results.

a) To assess tobramycin disposition in rat lungs using a realistic ex vivo model, the isolated
perfused rat lung preparation or IPRL. Tobramycin disposition in the rat lung following
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airway administration was studied as a function of dose and local concentration using a
previously described method (Byron and Niven, 1988). To explore the kinetics and
mechanisms of the drug’s absorption from the airways, the mean cumulative absorbed
fraction of each administered dose absorbed into the perfusate, Fp, was compared to that of
the absorption markers, fluorescein (known for its rapid and complete absorption) and
mannitol (known for its paracellular absorption), as a function of time following
administration. To support the development of a disposition model with the presence of
drug binding and/or sequestration to the lung tissues, dynamic dialysis of sliced IPRL
tissues was studied immediately after drug administration to the airways, to assess the
binding or tissue sequestration properties of tobramycin. These experiments and the
resultant kinetic model for tobramycin absorption and disposition in the IPRL are described
in detail in this thesis in Chapter IV.

b) To investigate the effects of osmolality and pH of dosing solutions on tobramycin’s
absorption from the airways of the IPRL. The potential airways’ anatomical and
functional alteration due to the administration of non-isotonic and non-physiologic pH
solutions to the airways has been reported to alter solute transport through the airways
(Beasley et al., 1988; Eschenbacher et al., 1984; Glauser et al., 1979; Schanker and Less,
1977). In the literature, the osmolality of tobramycin dosing solutions appears to be
theoretically unpredictable (Law, 2001) in that measurements have indicated much smaller
osmolality values than those based on theoretical calculations. Therefore, in some
experiments, in which absorption from the airways of the IPRL was studied, the osmolality
of dosing solutions was measured experimentally while in others, the effects of varying the
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concentration of NaCl (0.225-0.9% w/v) and/or the pH of the dosing solutions (tobramycin
concentration held constant) was assessed.

c) To evaluate the effect of tobramycin on airway epithelial integrity in the IPRL. Because
aminoglycosides and other polycations in certain concentration ranges have been reported
to affect epithelial integrity and/or alter solute permeation through epithelia in vitro and in
vivo (Dong et al., 2011; Todd et al., 1994), the effect of tobramycin on mannitol absorption
from the airways of the IPRL was investigated following co-administration of mannitol
with tobramycin at different concentrations to the airways. Because mannitol is accepted
as a marker solute for paracellular absorption through different epithelia, the approach was
used to elucidate whether the tobramycin itself could increase its own permeability at high
drug concentrations by affecting the airway epithelial integrity.
In summary, the work described in thesis Chapters III and IV focus on the evaluation of
tobramycin’s absorption and retention following airway administration in humans and rats,
respectively. These culminate in Chapter IV, where a disposition model is described that invokes
dose and concentration-dependent drug binding and/or sequestration to lung tissues to explain the
kinetic handling of tobramycin by the rat lung. Chapter V is aimed to validate and place constraints
on that disposition model by describing the results of experiments designed to eliminate the
possibilities that perturbations other than tissue binding or sequestration may have been
responsible for some of the effects predicted at concentrations likely to be seen following
inhalation.
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Chapter III *
PHARMACOKINETIC META-ANALYSIS TO ESTIMATE TOBRAMYCIN’S
PULMONARY BIOAVAILABILITY FOLLOWING INHALATION IN HUMANS

III.a INTRODUCTION

Inhaled tobramycin is recommended for the maintenance treatment of lung infections
associated with Pseudomonas aeruginosa in cystic fibrosis (CF) patients, as an alternative to
intravenous (IV) administration, in order to deliver high antibiotic concentrations direct to the site
of infection while minimizing the drug’s systemic toxicity (Cheer et al., 2003; Geller et al., 2002;
Touw et al., 1995). Although its efficacy and safety are well-recognized, tobramycin’s pulmonary
biopharmaceutics are not well understood in humans, partly due to the general technical difficulties
involved with (a) characterizing the true dose administered to the lungs by different pulmonary
delivery systems in the clinic and (b) the analytical challenges associated with determining the low
blood levels of tobramycin resulting from inhalation (McGlinchey et al., 2008; Pechere and Dugal,
1979).

Notably, there are no published studies in which tobramycin’s pulmonary bioavailable fraction,
F, of the total lung deposited dose (TLD) has been determined and none in which an IV reference
experiment has been performed in the same subjects. In CF patients, absorption has been estimated
*Some of this chapter has been published in Li and Byron (2012)

17

with reference either to nominal loaded doses placed in the delivery devices (e.g. ampoule label
claims added to nebulizer reservoirs) or the in vitro emitted doses from the chosen delivery system
(e.g. apparent output from a powder inhaler after the use by subjects) (Cooney et al., 1994; Geller
et al., 2002; Touw et al., 1997). Not surprisingly, pulmonary bioavailability estimates with no
consideration of the true doses delivered to the lung, show large variations across the literature,
due to the high variability in delivery efficiency of inhalation devices for different formulations,
as well as inter-individual variations associated with breathing patterns, respiratory physiology and
function, and the drug’s variant pharmacokinetics that are seen in CF patients.

In humans, aminoglycosides are neither plasma protein bound nor metabolized, and are mainly
distributed through the body’s extracellular compartments; excretion of the unchanged drug in
urine occurs via glomerular filtration with a small percentage of the filtered fraction reabsorbed by
the renal proximal tubules (Pechere and Dugal, 1979). Systemic bioavailability of this class of
drugs from the GI tract is very low, since the drugs’ blood levels concentration was reported to be
extremely low following oral administration (Jaresko and Alexander, 1995; Phillips and Shannon,
1997; Weber et al., 1995). Drug accumulation or tissue sequestration has been documented in the
labyrinth of the inner ear and the renal cortex of the kidney after IV administration; this is believed
to cause the ototoxicity and nephrotoxicity associated with most aminoglycosides (Selimoglu,
2007; Todd and Hottendorf, 1995). To deal with the toxicity of aminoglycosides, in
pharmacokinetic studies, a 3-compartment model has often been used that contains a so-called
“deep compartment”, responsible for drug accumulation or tissue sequestration (French et al., 1981;
Schentag, 1978; Schentag et al., 1978). However, the slow phase of elimination (γ), that is
associated with this deep compartment, was generally not easy to characterize, as it appeared about
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24 hours following IV administration with a half live of a few days, and there were analytical
difficulties assaying extremely low drug concentrations in these circumstances. In clinical practice,
after a single dose, the 2-compartment open body model, in which the rapid distribution phase
corresponds to fast distribution through fluid compartments and elimination occurs via renal
excretion, is generally sufficient to describe tobramycin disposition after IV administration
(Aminimanizani et al., 2002; Inclan et al., 2005).

In CF patients, aminoglycosides are generally believed to show different intrinsic
pharmacokinetic behavior to that seen in non-CF humans, with an increased total body clearance
(CL) and/or a larger volume of distribution (Vd) (Horrevorts et al., 1988; Levy et al., 1984). Larger
inter-subject variability in PK parameters, was also often seen in CF in comparison to non-CF
patients, probably because of the disease physiological and pathological complex (Mauro et al.,
1995; Town et al., 1996). From the point of view of aerosol delivery moreover, CF patients are
generally known to have mucus build-up in the airways and decreased mucociliary clearance,
because of the abnormal chloride ion secretion in the respiratory tract caused by reduced or absent
function of the cystic fibrosis transmembrane conductance regulator (CFTR) (Donaldson et al.,
2007). Overall, these factors in CF may contribute to further variability in tobramycin pulmonary
bioavailability following inhalation.

In this chapter, a meta-analysis is described that was performed using literature data to assess
tobramycin’s pulmonary bioavailability (the rate and extent of absorption of the lung deposited
dose) separately in CF and healthy adults. This meta-analysis combined the inhalation PK data in
which lung dose determinations were performed with tobramycin’s IV data from the literature.
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These PK data were re-evaluated by non-compartmental and compartmental approaches to assess
the pulmonary bioavailable fraction (F) and the apparent first-order absorption rate constant
following inhalation. In the effort to evaluate the absorption kinetics, the time-course of
tobramycin blood concentration profiles following inhalation were re-analyzed by deconvolution,
using the Loo-Riegelman method (Gibaldi and Perrier, 1975). This method is known as a very
useful and rigorous method for the evaluation of absorption kinetics that applies generally to linear
multi-compartment PK models (Gibaldi and Perrier, 1975) and is one that has been used
successfully in inhalation work when dealing with experimental data (Clark and Byron, 1986).

Following aerosol delivery and deposition in the lung, in the case that drug biological
transformation and degradation are absent in the lung, the converse of absorption is, of course,
drug retention in the airways. It is notable therefore, that tobramycin lung retention following
inhalation, should favor its antipseudomonal efficacy, and be a subject of interest to those studying
its clinical pharmacology and aerosol development (Patton et al., 2004; Ruddy et al., 2013). It is
hardly surprising therefore, that the sputum concentration of tobramycin following inhalation in
CF patients has been extensively investigated in many studies to assess the drug’s in vivo local
antibacterial activity, the apparent delivery efficiency of various inhalation devices, and even
tobramycin’s potential accumulation in the lung with repeated administration (Eisenberg et al.,
1997; Geller et al., 2003; Poli et al., 2007; Ruddy et al., 2013). The topic is complicated by the
difficulty in obtaining sputum samples for analysis that are in some way “representative” of the
drug’s “non-absorption” following delivery to different sites on an enormous epithelial surface. In
general therefore, there is high variability seen in tobramycin sputum concentrations following
inhalation, and it makes the results difficult to interpret. These variations are attributed to the
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different delivery efficiencies of devices, the time and methods to collect airway secretion samples,
and the human subject’s disease status and airway anatomy (Gibson et al., 2003). Nevertheless, to
gain more insight into drug retention in the airways, the available sputum PK data following
inhalation are systematically reviewed and discussed, in an attempt to add this information to the
meta-analysis. These data are not available for healthy humans in the literature and therefore, only
studies in CF patients were included in this analysis.

III.b METHODS

Pulmonary bioavailability
Tobramycin PK studies after IV and inhalation administration were systematically retrieved by
subject searching for “tobramycin pharmacokinetics” in PubMed (1968-2013 July) and manually
adding articles retrieved from the reference sections of key articles obtained from that PubMed
search. Studies were selected for analysis if they met the following Eligibility criteria:
1. Tobramycin PK data from adult CF or adult healthy humans with ages between 17 and 65
years old were included if the drug was administered either intravenously or by inhalation
and drug blood concentrations were determined for at least 5 time points after
administration (for IV studies, the sampling duration covered both distribution and
elimination phases, while for inhalation studies the sampling duration spanned both
absorption and elimination phases).
2. Impaired renal functions or critical illness were excluded to avoid unexpected changes in
clearance under these conditions (Leroy et al., 1978; Pechere and Dugal, 1976). Abnormal
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renal function was defined as creatinine clearance out of the normal range 80-160
ml/min/1.73 m2.
3. Research studies involving inhalation were selected only if the lung dose determination
could be assessed with confidence from the article in question.
4. Articles which failed to indicate that blood concentrations were greater than the reported
assay lowest limit of quantitation (LLOQ) were rejected as were those in which blood level
data were reported with sparse sampling schedules, such as those from routine therapeutic
drug monitoring using peak and trough levels.
The eligible data were categorized into CF and healthy groups, and analyzed separately by three
different methods to assess the rate and extent of tobramycin absorption following inhalation.

Method 1: This was a non-compartmental approach. The value of the fraction of the lung dose
that was absorbed at time infinity, F, was estimated from:
F= CL/(TLD/AUCinh)

eq. III.1

where AUCinh is the total area under the drug blood concentration versus time curve following
inhalation, CL is total body clearance and TLD is total lung dose; values for AUCinh were used
either as reported in the literature, or they were calculated trapezoidally. AUC values from the
ultimate concentration value (Clast) through time infinity were estimated from Clast/k where k was
the negative log-linear slope of the concentration versus time data collected during the elimination
phase in the inhaled drug study. The values of CL, for CF and healthy subjects, were obtained
separately by averaging the pooled data from the eligible IV studies in each population across the
literature, by taking the sum of the reported mean values for CL multiplied by the number of
subjects in each study and finally dividing by the total number of subjects across all studies. The
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mean (±SD where available) values of CL in each IV study was used as reported or in the event
that it was not reported, calculated from CL=β*Vβ or dose/
weight; β, Vβ and

and expressed per kg body

refer to the terminal first-order, whole body elimination rate constant,

the apparent volume of distribution and the total area under the concentration versus time curve
following IV administration from time zero to infinity, respectively; the values of the PK
parameters such as β, Vβ and

, were used as reported.

Method 2: This was based on curve fitting of the inhalation data to equations representing the
compartmental model shown in Scheme III.1. In this case, F with respect to the known value for
TLD was given by ka/(ka+knal), the ratio of the first-order absorption rate constant (ka) to the total
first-order rate constant for removal of drug from the lung following inhalation (equal to the sum
of ka and knal, where knal is the first-order rate constant responsible for non-absorptive loss). A 2compartment PK model was chosen to analyze both the IV and inhalation data, because that was
reported to provide the best description for tobramycin disposition following systemic exposure in
clinical trials (Aminimanizani et al., 2002; Inclan et al., 2005). The PK parameters
the apparent first-order intercompartmental transfer rate constants,

and

are

is the apparent first-order

elimination rate constant from the central compartment, and Vc is the apparent volume of the
central compartment. The values of kcp, kpc, kel and Vc for CF and healthy subjects were derived
separately from the IV data for each population. In short, the blood level versus time curves from
these IV studies were digitally copied and the concentration data at each time point extracted using
DataThief II (http://datathief.org), a graph reading java software and dose- and body weightnormalized where necessary. Curve fitting of the IV data was then performed in accord with a 2compartment PK model using non-linear regression and SCIENTIST® 3.0 (MicroMath, Saint
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Louis, MO), to provide best estimates for kcp, kpc, kel and Vc. Similarly, non-linear regression was
then employed to analyze the inhalation data in accord with Scheme III.1, where the values of kcp,
kpc, kel and Vc were held constant at the best estimates obtained from the IV data. TLD was fixed
at its reported value while ka and knal were allowed to float to produce the best curve fits of the
inhaled blood level versus time data, plus best estimates for ka and knal and F.

TLD

Lung

ka

Central
Compartment
Vc

knal

kcp
kpc

Peripheral
Compartment
Vp

kel

Scheme III.1 Pharmacokinetic model describing pulmonary clearance, absorption, distribution and
elimination of the inhaled tobramycin total lung dose, TLD. First-order rate constants ka, knal, kpc,
kcp, and kel represent absorption into the central sampled compartment with apparent volume Vc,
non-absorptive loss from the lung, distribution between the central and peripheral compartment
with apparent volume Vp, and elimination, respectively.
Method 3: The Loo-Riegelman method (Gibaldi and Perrier, 1975) was used to assess the
absorption properties of tobramycin following inhalation; the intrinsic PK parameters of this twocompartment open body model drug were determined in CF and healthy subjects as described
above (Method 2). The percent of TLD absorbed at time t, abs%, was then calculated by eq. III.
2-5 calculated (Gibaldi and Perrier, 1975):
%

100%

eq. III.2
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where

eq. III.3
∆

∆

∆
∆

and

∆

∆

1 /

eq. III.4
eq. III.5

and
are the amount of drug absorbed systemically at time t, and the amount of drug
where
that is ultimately absorbed, respectively;
and
, are the amounts of drug in the peripheral
compartment at the time of the first of any two consecutive sampling periods (i.e. t = t1) and at
time t, while
is the amount of drug in the central compartment at the time of the first of the
and
are the area under the plasma concentration versus time curve
sampling period;
from time zero to time t, and from time zero to infinity, respectively;
is the drug plasma
in each period of time, ∆
.
concentration at time t and ∆ is the change of
The percentage remaining unabsorbed (100 - abs%) versus time plots were generated and used to
predict the absorption rate constant for tobramycin after administration to the airways, assuming
that absorption occurred only via the lung.

Sputum pharmacokinetics
Tobramycin concentrations in sputum sampled from adults and children (Ages ≥6 years) with
CF after single or repeated inhalation doses were obtained from the systematic literature review
described above. The subset of articles that were used for a review of sputum concentrations
included those by Griese et al., 2013, etc. shown in Table III.4. To evaluate the variability
associated with different study designs and methods, the drug formulations and delivery devices
for inhalation, and the dosing and sampling regimens in these studies were tabulated and
summarized. The values of C

, the “peak” sputum concentration, generally determined from

samples taken 10-60 minutes post administration, and C

, the pre-dosing level, as well as

, area under the tobramycin sputum concentration time curve, immediately after dosing
to the last sample time point (8 or 12 h), were compared across these studies to evaluate the
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evidence for potential lung retention and/or accumulation of tobramycin in sputum after repeated
inhalations.

III.c RESULTS AND DISCUSSION

Pulmonary bioavailability
A total of 633 papers were obtained from the keyword search in PubMed. Of these, only 18
studies satisfied the Eligibility criteria for meta-analysis to determine tobramycin’s pulmonary
bioavailability. The eligible studies included 15 IV PK studies in adult humans. IV studies were
categorized into 2 groups: CF (6 studies) and Healthy (9 studies). For the inhalation PK studies,
two studies that met the Eligibility criteria were included: Pilcer et al. 2008 (in CF adults) and
Newhouse et al. 2003 (in healthy adult volunteers), while a similar study by Lenney et al. was
excluded from the meta-analysis because of the data insufficiency in this paper for the estimation
of F or the absorption rate constants by Method 1, 2 and 3 (Lenney et al., 2011). In the inhalation
studies, the lung doses were estimated using γ-scintigraphic imaging to characterize the deposited
dose in the lung, after labeling formulations with

99m

Tc before administration (Newhouse et al.,

2003; Pilcer et al., 2008)

Method 1
The weighted mean value for tobramycin total body clearance (CL) was 1.88 ml/min/kg in CF
adults, obtained from a total of 50 subjects in six IV PK studies, and 1.23 ml/min/kg in healthy
adults, from a total of 80 subjects in nine IV studies. The individual reports and values are
summarized in Table III.1. These clearance values are believed to be typical in these populations
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and are consistent with excretion that occurs primarily via glomerular filtration. Notably, in the IV
studies, values of CL for CF patients were generally larger than those for healthy subjects, although
substantial variations were associated with both populations. The relatively larger values seen in
CF were consistent with the findings of many other studies, in which an increased volume of
distribution and CL were seen in CF (de Groot and Smith, 1987; Levy et al., 1984). The reasons
for this PK change in CF patients remain unclear; enhanced renal clearance, diminished tubular
reabsorption or an additional alternative route of excretion such as respiratory or gastrointestinal
elimination in CF have all been mentioned (Horrevorts et al., 1985; Levy et al., 1984).

For CF patients in Pilcer’s study (2008), using the values of CL obtained from IV studies, the
average estimates of F for 3 formulations administered in different doses, were 1.03 (lipid-coated
dry powder), 1.09 (uncoated dry powder), and 1.70 (nebulized TOBI®) (Table III.2). The
unrealistically high absorbed fraction, F >> 1 for the aqueous TOBI® formulation, delivered by a
hand-held PARI LC Star nebulizer (PARI GmbII; Starnberg, Germany), could have been due to
either the choice of an inappropriate CL value for Pilcer’s patients (Table III.1) or an experimental
underestimated TLD assessment by Pilcer et al. (2008). The inaccuracy in the case of TOBI® may
also indicate that values of F from Pilcer’s powder formulations, delivered by the
aerolizer® (Novartis, Switzerland), are also unreliable (Table III.2).
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Table III.1 Total body clearance values for tobramycin reported or calculated from IV PK
studies in CF and normal human adults
CF
Ref
Butterfield 2013

Healthy
n

CL*
(ml/min/kg )

9

1.2±0.2

Moriarty 2007 14

n

CL*
(ml/min/kg )

Champoux 1996

12

1.3

1.6

Mauro 1995

8

1.2±0.1

Woodworth 1994

6

1.2±0.1

Ref

Aminimanizani 2002

6

2.0

Bates 1997

8

1.4±0.4

Pleasants 1988

15

1.4

Cooney 1994

6

2.5±0.3

Guglielmo 1987

8

1.3±0.2

Horrevorts 1985

7

3.1±0.9

Winslade 1987

11

1.2±0.4

Pcherere 1976

4

0.8

Lode 1975

12

0.9

Regamey 1973

4

1.8±0.1

Total
50
1.88**
Total
80
1.23**
* mean (±SD where available) as quoted or calculated (CL=β*Vβ or dose/AUC∞) and
normalized for reported body weight; ** weighted mean by sample size from each study.

Method 2
The compartmental curve fitting approach, advocated by Sakagami (Sakagami, 2004) to
determine the absorption of drugs following inhalation, also relied on the accurate assessment of
intrinsic PK parameters determined from IV data in a different subject cohort; however values of
F >>1 cannot be obtained using this method (Scheme III.1). In this case, two of the previously
selected IV studies: Aminimanizani et al. (2002, for CF adults) and Pleasants et al. (1988, for
healthy adults) were selected for analysis, mainly because (a) those two studies showed most
frequent sampling over a sufficient length of time (more than 8 hours) following IV administration
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and (b) the assay methods were believed to be reliable (Aminimanizani et al., 2002; Pleasants et
al., 1988). The assay methods, fluorescence polarization immunoassay (TDX; Abbott Laboratories,
Irving, TX), used in those two studies, were judged to be sensitive, accurate, precise and
reproducible, compared to other analytical methods, such as enzyme-multiplied immunoassay
(EMIT), radioenzymatic assays and microbiological assays used by others (Cheng et al., 1987;
Touw et al., 1996). Best estimates of Vc, kcp, kpc, and kel for the IV data in Aminimanzani et al. and
Pleasants et al. obtained using non-linear regression in accord with 2-compartment open model are
shown in Table III.3 alongside values for the model selection criterion, MSC, and coefficient of
determination, COD, both of which indicated excellent fits to the data.

Table III.2 Values for F from analysis of inhalation PK data for tobramycin by Methods 1 and 2
Lung deposited
dose(mg)/% of
nominal

F
Method 1

Method 2a

Pilcer 2008 (CF)
Lipid-coated powder from DPI

12.6/53.0%

1.03

0.99

Uncoated powder from DPI

8.5/34.1%

1.09

NE

TOBI® (PARI LC Star)

22.8/7.6%

1.70

NE

Newhouse 2003 (Normal)
DPI

27/34.3%

0.83

0.85

TOBI® (PARI LC PLUS)

15/5.0%

0.78

0.76

a

Values shown for curve fits in Figure III.2;
NE = not estimated (data fit not possible with fixed PK; Table III.3)
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Table III.3: Pharmacokinetic parameters estimated by curve fitting IV tobramycin blood
level data to a 2-compartment open body model a
Data Source
(ref)
Aminimanizani
2002
Pleasants 1988

0.178
(0.033-0.208) d

kcp
(hr-1)
0.92
(0.24-1.94) d

kpc
(hr-1)
1.00
(0.53-3.16) d

kel
(hr-1)
0.64
(0.43-2.43) d

0.125
(0.112-0.137) e

1.28
(0.75-1.91) e

1.66
(0.99-2.33) e

0.65
(0.55-0.75) e

Vc (L/kg)

MSC b

c

r2

4.1-6.5

0.9960.999

4.8

0.998

a

Gibaldi and Perrier, 1975; b Model Selection Criterion; c coefficient of determination; d median
value (range) of the best estimates from 6 individual blood drug concentration versus time curves;
e
best estimate (95% CI) from curve fitting the mean blood drug concentration versus time curve.
In the study of Newhouse et al. in healthy volunteers, the PK data for a tobramycin dry powder
(PulmoSphereTM formulation; PStob; Inhale Therapeutic Systems; San Carlos, CA) delivered from
a passive dry powder inhaler, was also compared to those from a commercial nebulized tobramycin
product TOBI® delivered by PARI LC Plus nebulizer (Newhouse et al., 2003). The values of F
were 0.83 for the powder formulation and 0.78 for nebulized TOBI® (Table III.2). Despite these
apparently “reasonable” estimates for F, the wide variation seen around the average value of CL
(1.23; reported range 0.8 - 1.8 ml/min/kg) for normal subjects that were used to analyze these data
(50 adults, Table III.1) did not inspire confidence in this assessment of tobramycin’s pulmonary
bioavailability. Overall, the results of Method 1 were inconclusive with respect to F, largely
because of uncertainty in values for CL. Even so, the data were indicative of substantial pulmonary
absorption, in spite of the known poly-cationic state of this drug at physiologic pH (Szilagyi et al.,
1993). As expected (Weber et al., 1995), there was also little evidence seen for any contribution
of GI absorption to tobramycin blood levels following pulmonary administration.
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In the inhalation study for healthy subjects, the Newhouse data (Newhouse et al., 2003) showed
good agreement with the PK model described in Scheme III.1, as shown in Figure III.1. The
calculated F values are shown in the final column of Table III.2. The values of F in normal subjects
for nebulized TOBI® and dry powder were 0.76 and 0.84, respectively, consistent with the values
calculated by Method 1. The estimates for ka ranged 0.30 – 0.41 h-1 in normals, corresponding to
absorption half lives 1.7-2.3 hours, close to that of technetium-99 m-labelled diethylene triamine
pentaacetic acid (99mTc-DTPA), a hydrophilic solute with a similar molecule size as tobramycin
and recognized as a paracellular absorption marker following aerosol administration in human
(Bondesson et al., 2007; Coates and O'Brodovich, 1986). For CF patients in the study of Pilcer et
al. (2008), however, the method failed to provide good fits to the inhalation data for the treatment
groups using both nebulized TOBI® and the uncoated powder; plasma concentrations in Pilcer,
that apparently resulted from the reported TLD, could not be reached in simulations with this
model, even when very large ka values were employed. It is possible that underestimation of TLD
and/or variations in the drug’s intrinsic PK between patient cohorts were responsible for this
apparent “failure” in curve fitting, but this also means that the estimate of F from Method 2 (=
0.99, Table III.2) for Pilcer’s CF patients must also be viewed with suspicion, alongside the value
for ka (= 1.0 h-1, Figure III.1). Notably, the possible underestimation of TLD in Pilcer’s study,
discussed for Method 1, above, could also be the explanation for the results seen here, even though
two quite different approaches were used for calculation.
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Figure III.1 Mean tobramycin blood level versus time curves following inhalation; data from Pilcer
et al.(2008) and Newhouse et al.(2003). Best fits using nonlinear regression analysis to the PK
model in Scheme III.1 according to Method 2 are shown as curves in which all rate constants other
than ka and knal were held constant at the values shown in Table III.3. Pilcer data for formulations
other than the lipid coated powder could not be fitted with the fixed rate constants shown in Table
III.2 (NE in Table III.2). Estimates for the absorption rate constant ka were 1.00, 0.41 and 0.30 h-1
for Pilcer (TOBI®), Newhouse (DPI) and Newhouse (TOBI®), respectively.
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Method 3
When the Loo-Riegelman method was used to analyze the data in the study of Newhouse et al.
(2003) , the amount of bioavailable drug calculated for the nebulizer formulation TOBI® and the
dry powder formulation was 12.2 mg (TLD=15 mg) and 26.1 mg (TLD=27 mg), corresponding to
values for F = 0.82 and 0.97, respectively. These results were consistent with those from Methods
1 and 2, indicating tobramycin’s pulmonary bioavailability as close to 100%. The percentages of
drug remaining unabsorbed (100 - abs%) versus time plots (Figure III.2) in log-linear plots for
both formulations indicated that tobramycin absorption from the lung appeared to be first-order.
For Method 3 however, the absorption half lives fell in the range from 2.7-3.4 hours. Pilcer’s data
from CF patients for the nebulizer TOBI® could also be analyzed using this technique yielding the
values for the bioavailable dose equal to 48.2 mg, more than two fold higher than the experimental
determined lung deposited dose (22.8 mg) stated in the paper. For the lipid-coated and the uncoated
drug powder formulation, the bioavailable doses were estimated at 15.3 mg and 11.4 mg,
corresponding to 21 and 35% higher than the reported TLD for these two formulations,
respectively. Clearly, these values for TLD, and the apparently non-linear absorption profiles in
Figure III.2, for CF patients, were influenced significantly by the chosen estimates for the drug’s
intrinsic PK parameters; those were derived entirely from the data of Aminimanizani et al. (2002),
and they may well be unrepresentative of the behavior of tobramycin in Pilcer et al.’s patients.
Notably however, given intrinsic PK parameters from selected IV experiments that are
representative of a drug’s behavior following extravascular absorption, this approach (Method 3)
may be an acceptable deconvolution method capable of determining independently, a value for the
bioavailable dose.
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Figure III.2 Semi-Log plot of percentages of bioavailable tobramycin remaining to be absorbed
versus time following inhalation. Percentages of bioavailable tobramycin remaining to be
absorbed were calculated for the inhalation formulations in the studies of Pilcer et al.(2008) and
Newhouse et al.(2003) by the Loo-Riegelman method (Gibaldi and Perrier, 1975). The apparent
absorption half lives were 3.4 hr (nebulizer TOBI) and 2.7 hr (the DPI) for the data from healthy
adults in the study of Newhouse et al.(2003), and 3.2, 3.3 and 3.4 hrs for the nebulizer TOBI,
lipid-coated and uncoated DPI, respectively, in the study of Pilcer et al.(2008) on CF patients.

Notably, tobramycin absorption data (the percentages of drug remaining unabsorbed (100 abs%) versus time) from the CF patients in the study of Pilcer et al. (2008) showed a slight
deviation from mono-exponential absorption kinetics, showing a suspected biphasic absorption
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behavior. One explanation for this apparent biphasic absorption behavior may possibly be
decreased mucociliary clearance caused by mucus build-up, often associated with CF patients
(Donaldson et al., 2007). Alternatively, drug binding and/or sequestration in lung tissues, that tends
to prolong the drug’s absorption after airway administration, may also be responsible for this
biphasic absorption.

Sputum pharmacokinetics
Ten studies in CF patients were analyzed in an attempt to evaluate tobramycin concentration
data in sputum following repetitive dosing by inhalation. Table III.4 shows the summary of sputum
PK studies that were considered. After inhalation of tobramycin solution (either 300 mg in 4 mL
of ½ normal saline (1/2NS) or 300mg in 5 mL ¼ NS were delivered by nebulizer, the drug sputum
concentration could exceed by more than 100 times the reported tobramycin minimum inhibitory
concentrations (MICs) for Pseudomonas aeruginosa; MICs have been shown to vary between 0.5
and 32 mg/L for isolates obtained from patients with cystic fibrosis treated with once- or thricedaily intravenous tobramycin while the MIC90 (MIC required to inhibit the growth of 90% of
organisms) after inhalation treatment was reported as 16 mg/L (Burkhardt et al., 2006; LiPuma,
2001). These high drug levels in sputum have been used in the literature to imply antimicrobial
efficacy after local drug delivery to the lung.

Despite the large variations between subjects, the mean or median C

and

,

were comparable between studies, given comparable formulations and delivery systems, e.g.
TOBI® (300 mg/5mL in ¼ NS and pH 6.0) delivered by PARI LC PLUS® (Table III.4). The
eFlow® nebulizer was reported to achieve a higher C
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than the PARI LC PLUS® in one study

(Hubert et al., 2009), while this conclusion was not reached by others (Govoni et al., 2013; Griese
et al., 2013), possibly due to large inter-subject variations. The values of tobramycin sputum
concentrations determined in the study of Griese et al.(Griese et al., 2013) were relatively higher
than those of other studies using the same formulation and delivery system for unknown reasons,
although the high variability seen in sputum concentrations appear to be due mostly to variable
inhalation and deposition patterns, airway obstruction and anatomy differences seen with age and
disease, mucus plugging, individual sputum production rates and the use of different assay
methods for sputum samples (Hubert et al., 2009).

Tobramycin retention and accumulation in the lung following inhalation were generally
assessed by evaluation of the drug’s persistence after a single dose and the changes in “peak” and
values after repeated dosing. Theoretically,

“trough” sputum concentrations, as well as

the drug peak concentrations in sputum may behave most likely as a surrogate of initial deposition
in the airways and could be very variable (Okubo and Iyobe, 2002). Drug trough concentrations in
sputum determined pre-dosing (approximately 12 h following last inhalation) can probably better
reflect the true concentrations in the lung, since drug deposited in the upper airways such as
laryngopharynx and trachea can be removed by clearance and swallowing within a couple of hours.

In general, tobramycin concentrations in sputum rapidly decreased 1-2 h after administration of
TOBI® by PARI LC PLUS®, and then became undetectable 3 to 12 h after a single dose by
inhalation, indicating rapid removal of this drug from the lung, by absorption into the systemic
circulation, mucociliary clearance and swallowing. However, the values of trough tobramycin
concentrations at steady state (pre-dose drug concentration in sputum at day 15 or day 28) after
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twice daily dosing were reported to be 148±354 μg/g and 135±93 μg/g, by Hubert et al. in children
and Govoni et al. in adults, respectively, implying that some drug accumulation occurred in the
airways after repeated dosing, and not all of the administered dose is absorbed 12 hours after
inhalation. Consistent with that data for escalated trough levels, tobramycin was found to
accumulate 3.7-fold in the sputum with eFlow® and 2.1-fold with PARI LC PLUS®, shown by the
ratio of sputum AUC0-8h between Day 15 and Day 1 in the study of Hubert et al. In contrast
however, the study of Govoni, et al. reported tobramycin accumulation in sputum after 28 days’
dosing (twice daily) as “low”, because the ratios of C
1.06 for C

and 1.61 for

and

(geometric mean at

) between Day 28 and Day 1 differed insignificantly

from unity (Govoni et al., 2013). In Govoni et al.’s study however, the large inter-subject variations
seen in sputum concentrations likely disguised the possible change in C

and

,

caused by repeated dosing (Govoni et al., 2013).

In another study, tobramycin accumulation in the lung after 28 days’ repeated dosing (twice
daily) by inhalation in CF patients was evaluated in children less than 6 years old, using tobramycin
concentrations in epithelial lining fluid (ELF) collected by bronchoalveolar lavage (BAL) (Gibson
et al., 2003). The drug concentrations in ELF are believed to be more representative of levels in
the deep lungs, compared to drug concentration in the sputum sample (Tayman et al., 2011),
although ELF is more difficult to collect and concentration data more difficult to interpret.
Nevertheless, tobramycin was detectable in ELF an average 12 h after the last dose at Day 28, with
a mean (±SD) concentration of 74 (±50) μg/mL (Gibson et al., 2003). Compared with the mean
(±SD) drug concentrations of only 90 (±54) μg/mL in ELF at the “peak” level (45 min after
inhalation) and generally undetectable concentrations after 12 h after a single or first dose (Gibson
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et al., 2003; Rosenfeld et al., 2001), these results clearly indicated drug accumulation in the lung
after repeated doses. High trough drug levels in the ELF of young children at steady state,
combined with the sputum results in CF patients in the studies of Govoni, et al. (2013) and Hubert
et al.(2009), with ages ≥6 yrs, all support a finding of tobramycin retention and accumulation in
respiratory secretions when repeated inhalation occurs in CF patients.
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Table III.4 Summary of sputum pharmacokinetics for tobramycin following inhalation in CF
patients.
Ref

Govoni
2013

1

N

27

Griese
2013

76

Ruddy
2013

10

Hubert
2009

25

Lenoir
2007

21

Poli 2007

11

Geller
2007

84

Geller
2003

49

Eisenberg
1997

Weber
1994

60

7

Age of
subjects
yrs

Sputum
sampling
times(post
-dose)

≥18

0.5, 1.5, 3
and 8 h on
day 1 and
day 28

average
20

≥10

≥6

≥6

18-37

≥6

15-36

11-41

≥7

10 min at
day 7
0.5-0.6 h
on day 2 3 and day
26-28
0, 0.5,1.5,
2 and 8 h
on day 1
and day
15
0.5 h on
day 1 and
day 28
0.5, 3,
6,12,24 h
0.5, 1, 2,
4, 8 and
12 h
0.2,1, 2,4
and 8 h

10 min, 1
and 2 h

0.05, 1, 2,
3, 4 h

First day
Device/
Formulation
PARI eFlow®
(300mg/4mL)

2

(mean±SD)
ug/g
540.8
±676.5

Last day
2

3

(mean±SD)
μg*hr/g

(mean±SD)
μg/g

3

(mean±SD)
μg*hr/g

529.4±714.4

518.6±639.7

529.4±714.5

PARI LC
PLUS®
(300mg/4mL)

491.3
±690.1

573.1±706.6

819.9±1611.1

758.8±1470.4

PARI eFlow®
(150mg/1.5mL)

NR

ND

4,8
2589
(1967,3211)

ND

PARI LC PLUS®
(300mg/5mL)

NR

ND

4,8
2272
(1659,2885)

ND

PARI LC PLUS®
(300mg/5mL)

5
961.0
(681.5,1.536)

ND

5
1323
(520,1730)

ND

PARI eFlow®
(300mg/5mL)

981±1191

1688±2046

1572±2182

3731±7235

PARI LC PLUS®
(300mg/5mL)

754±927

1511±1744

769±823

1941±2301

PARI LC PLUS®
(300mg/4mL)

9

ND

9

ND

1289±851

NR

ND

ND

816±681

NR

ND

ND

737±1028

974±1143

ND

ND

1048±1080

1275±1359

ND

ND

959±952

1307±978

ND

ND

985.7±839.3

1471±1278

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

NR

ND

ND

PARI LC PLUS®
(300mg/4mL)
PARI LC PLUS®
(300mg/5mL)
PARI LC PLUS®
(300mg/5mL)
T-326 DPI
(4*28mg)
AeroDose® 5.5
RP
(90 mg/1.5 mL)
PARI LC PLUS®
(300mg/5mL)
UltraNeb
(600mg/20mL)
Sidestream
(300mg/5mL)
PARI LC®
(300mg/5mL)
Pulmo-Aid
(80mg/4mL)
1

695.6±817.0

6

1359
(44-7782)
6
393
(57-1998)
6
452
(47-3724)
7

325 (59-629)

716.9±799

NR: not reported; ND: not determined; number of subjects; 2 the “peak” sputum concentration,
generally determined from samples taken 10-60 minutes post administration; 3 area under
concentration versus time curve for tobramycin in sputum determined trapezoidally in each study;
t = the last time points for sputum determination; 4 mean (90%CI); 5 median (25th, 75th percentiles);
6
median (range); 7 mean (range); 8 sputum concentrations determined on day 7; 9 concentration
unit in μg/mL.
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III. d CONCLUSIONS

In summary, the absorption of tobramycin from the lung appears to occur slowly but to be more
complete than is commonly assumed based on the drug’s theoretical behavior as an
aminoglycoside poly-cation at physiologic pH (Szilagyi et al., 1993). The large variance seen in
published studies of tobramycin’s intrinsic pharmacokinetics (IV) precluded accurate assessment
of its pulmonary bioavailability. A cross-over study, where drug plasma level versus time profiles
are compared following IV and inhalation administration to the same subject cohort, is needed to
eliminate the uncertainties associated with the evaluation of its fractional pulmonary absorption
(F) in humans. In CF patients, tobramycin absorption from the lung following inhalation appeared
to occur more rapidly than in normals but this could not be stated with certainty from the drug’s
pharmacokinetic data. The results from the sputum PK meta-analysis however, indicated that drug
retention and accumulation in the lung following inhalation appeared to occur after repeated dosing,
at least in CF patients. It was possible therefore, that some mechanism for tobramycin binding
and/or sequestration was involved in extending the drug’s retention at the site of its action in
humans. Further investigation into the kinetics and mechanisms of tobramycin disposition
following airway administration in animals could thus be an alternative way to explore the drug’s
binding and/or sequestration in lung tissues.

40

Chapter IV*
TOBRAMYCIN DISPOSITION IN THE RAT LUNG FOLLOWING AIRWAY
ADMINISTRATION

IV.a INTRODUCTION AND THEORY

Administration of tobramycin directly to the airways via nebulizer has brought great
improvements to the health and wellbeing of cystic fibrosis (CF) patients and others suffering from
chronic pulmonary infections with pathogens such as Pseudomonas aeruginosa (Chuchalin et al.,
2009).The efficacy and safety brought about by topical use of this drug is well-recognized in
clinical circles, although it remains unclear whether the antibiotic’s physicochemical properties
lead to slow absorption, tissue binding and/or lung retention to sustain the drug’s anti-infective
properties for periods between dosing (Li and Byron, 2012; Patton et al., 2004). Notably,
tobramycin is believed to cross epithelial barriers poorly and it is therefore marketed primarily as
an injectable (Jaresko and Alexander, 1995; Phillips and Shannon, 1997). Our recent meta-analysis
of pharmacokinetic data in humans following IV and inhalation administration found that it was
not possible to come to a statistically sound conclusion about its bioavailability and possible
binding to, or sequestration in, lung tissue following inhalation administration due largely to the
variance associated with the available data (Li and Byron, 2012), even though tobramycin and
*The body of the text in this Chapter is reproduced (without the abstract) directly from the published work of
the same title by Li M and Byron P.R. (2013) Journal of Pharmacology and Experimental Therapeutics 347:
318-24.
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other aminoglycoside antibiotics are known to manifest some of their toxicity through tissue
binding or sequestration and the creation of “deep compartments” (Mingeot-Leclercq and Tulkens,
1999; Nagai and Takano, 2004; Stepanyan et al., 2011). Notably, and probably because of the
physiologic existence of these drugs as polycations, transfer into cells is slow and intracellular
sequestration can be persistent. For these reasons we have used the isolated perfused rat lung (IPRL)
to systematically investigate the disposition of tobramycin in the lung following its administration
directly to the airways. The IPRL has been used similarly before (Byron et al., 1986; Niven and
Byron, 1988; Niven et al., 1990; Sakagami et al., 2002). In the most simple cases, when solutes
like fluorescein are administered in solution to the airways of this preparation, they behave in
accord with Scheme IV.1. Absorption of fluorescein then occurs in a dose-independent, first-order
fashion with no evidence of binding or metabolism. However, the nominal dose, or dose loaded
into a dosing cartridge (Figure IV.1) usually results in a smaller administered dose (D) (Scheme
IV.1), only part of which, the absorbable amount, A (A = D - U), where U is the transferable
(unabsorbable) amount of each dose, can be transferred to the perfusate (P). This is because the
bronchial circulation in the IPRL is severed and only solute that deposits proximal to the actively
perfused pulmonary circulation can be absorbed into the perfusate (Byron et al., 1986; Niven and
Byron, 1988). In such a case, solute in perfusate will increase mono-exponentially toward an
asymptotic value equal to the initial condition, A0. The fraction of the administered dose (D)
transferred to the perfusate (Fp) for a solute described by Scheme IV.1, is given as a function of
time, t:
1

e

eq. IV.1

where Fa is the absorbable fraction (= A0/D) and ka is the apparent first-order rate constant for
absorption.
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U

D

A

ka

P

Scheme IV.1 Kinetic models describing solute (fluorescein) dosing and absorption from the
airways of the IPRL in the absence of tissue binding or sequestration. Compartmental
abbreviations show the administered dose (D), the untransferable (unabsorbable) amount of
each dose (U), and the absorbable amount, A, (D=U+A), where P is the amount absorbed into
the perfusate at time t. The apparent first-order rate constant for absorption from the airways is
designated as ka.

In the case of other non-metabolized drugs that are absorbed by apparent first-order kinetics,
binding or sequestration to lung tissue can be modeled in accord with Scheme IV.2. This Scheme
differs from Scheme IV.1 because of the addition of a “bound drug” compartment (B) and the
association and dissociation rate constants (k12 and k21). In Scheme IV.2, which is analogous to a
two-compartment pharmacokinetic model, the drug in A and B should behave in a similar fashion
to drug in plasma and drug in tissue, respectively, whereas drug in P should behave in the same
way as cumulative elimination. Thus, the fraction in the perfusate, Fp, for Scheme IV.2 is given
by a rearranged form of eq. 216 from Gibaldi and Perrier(Gibaldi and Perrier, 1975) and the data
for drug in perfusate should conform to
p

a∗ 1

e

e

eq. IV.2

where

4

/2

and

4

/ 2.
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U
k21

D
A

ka

B
k12
P

Scheme IV.2 Kinetic models describing solute (tobramycin) dosing and absorption from the
airways of the IPRL in the presence of tissue binding or sequestration. Compartmental
abbreviations show the administered dose (D), the untransferable (unabsorbable) amount of
each dose (U), and the absorbable amount, A, (D=U+A), whereas P and B are the amount of
drug absorbed into the perfusate and the amount of drug bound to, or sequestration in, tissue at
time t, respectively. The apparent first-order rate constant for absorption from the airways is
designated as ka, whereas k12 and k21 are first-order association and dissociation rate constants
for binding or sequestration.

In this current study, the dynamic dialysis techniques, first described by Meyer and
Guttman and used subsequently by other groups to study solute-ligand binding (Bottari et al.,
1975; Hashimoto et al., 1984; Hiji et al., 1978; Meyer and Guttman, 1968; 1970; Pedersen et
al., 1977; Sparrow et al., 1982), were first used to support the use of the IPRL binding and
sequestration model described in Scheme IV.2. When dynamic dialysis under sink conditions
is used to extract solutes from sliced IPRL tissue following initial airway dosing to that tissue,
a model analogous to Scheme IV.2, Scheme IV.3 applies (Meyer and Guttman, 1968). In
contrast to Scheme IV.2, Scheme IV.3 lacks an untransferable component, i.e. U = 0, because
all of D that is administered to the airways becomes available for dialysis, so the amount
released into the receiver solution, R, becomes equal to D as t tends to infinity. Furthermore,
the binding or sequestration rate constants, k12' and k21', differ from those in Scheme IV.2
because sliced tissue and drug release from the dialysis sac differ from the intact IPRL. The
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first-order rate constant for solute release, ke, from a dialysis sac into R depends largely on the
diffusive properties of the solute and the conditions of dialysis. However, the fraction of
administered dose remaining in the sac (At /A0), at time t, should be a reflection of the solute’s
tissue binding, and should theoretically conform to eq. 218 from Gibaldi and Perrier (Gibaldi
and Perrier, 1975) , where
e

e
′

in which
and

β

′

eq. IV.3

′

′

′

′

′
′

4
4

′
′

/2
/2

k21'
A

D

B
k12'

ke
R

Scheme IV.3: Kinetic model describing solute dosing and dialysis from the IPRL in the
presence of tissue binding or sequestration; the dialysis sac is shown diagrammatically as
a dashed line. Compartmental abbreviations show the administered dose (D) and the
dialyzable amount, A, (A=D), while R and B are the amount released into the receiver
solution and the amount of drug bound to or sequestered in tissue at time t, respectively.
The apparent first-order rate constant for dialysis is designated as ke, while k12' and k21' are
the association and dissociation rate constants for binding/sequestration to the sliced
tissue.

IV.b MATERIALS AND METHODS
Experimental Design. Tobramycin, mannitol and fluorescein were administered in different
aqueous solution formulations, by forced intratracheal instillation, to the airways of the
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isolated perfused rat lung preparation (Figure IV.1) using a previously described method
(Byron and Niven, 1988). Using this technique, studies were performed to explore the kinetics
and mechanisms responsible for tobramycin’s pulmonary disposition. IPRL Absorption
Studies were performed to elucidate the effects of concentration on airway-to-perfusate
transfer (absorption). Prior to the analysis of data from those studies, IPRL Binding Studies
were performed using dynamic dialysis (Meyer and Guttman, 1968). Those binding
experiments employed identical surgical preparation, perfusion and airway dosing as those
for IPRL Absorption Studies, after which the extent and rate of tobramycin and/or mannitol
dialysis from lung tissue was determined.

Figure IV.1 The IPRL preparation showing perfusate circulation. The lung was suspended
horizontally in the artificial glass thorax (AGT) after cannulation of the pulmonary artery
and trachea (Sakagami, 2006).
Animals. Specific pathogen-free, 300–400g, male Sprague-Dawley rats (Hilltop Lab
Animals Inc., Scottsdale, PA) were used throughout. The animals were housed with access to
water and food at 30-70% relative humidity (RH) and 18-26˚C, and a 12-hr light/dark cycle
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for ≥ 2 days before sacrifice. All procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) at Virginia Commonwealth University.

Chemicals and Materials. Tobramycin (≥98% free base) and bovine serum albumin,
BSA, ≥98% (agarose gel electrophoresis) lyophilized powder (Sigma-Aldrich, St Louis, MO)
were stored according to USP-NF 2007 (United States Pharmacopeia and National Formulary,
2007) . Krebs-Henseleit solution (KHS) containing 4% (w/v) BSA (K4) was freshly prepared
and used as perfusate in the isolated perfused rat lung preparation. [3H]tobramycin and
[3H]mannitol solutions (0.8 Ci/mmol, 1 mCi/mL; 10-30 Ci/mmol, 1 mCi/mL, respectively)
were purchased from Moravek Biochemicals (Brea, CA) and PerkinElmer Life and Analytical
Sciences (Waltham, MA), and sodium fluorescein (F-Na) was obtained from Arocos Organics
(Geel, Belgium). Ecoscint XR scintillation cocktail (National Diagnostics, Atlanta, GA) was
used for liquid scintillation counting. Other chemicals were purchased from Fisher Scientific
(Pittsburgh, PA). Dialysis Tubing (Snakeskin®, 10K molecular weight cut-off, MWCO;
Thermo Scientific, Rockford, IL) was washed with water and immersed in aqueous buffer
solutions for >30mins prior to use.

Dosing Solutions. Aqueous radiolabeled tobramycin solutions were prepared in different
concentrations (100, 20, 2, 0.2, 0.04 and 0.02 mg/mL) containing a nominal radiolabel content
of 18 µCi/mL in 0.45% w/v NaCl and adjusted to pH 7.4 with H2SO4. Radiolabeled mannitol
was prepared with different concentrations at 12 µCi/mL, while sodium fluorescein (unlabeled)
solutions were prepared in pH 7.4 phosphate buffer and used at a concentration of 0.2 mg/mL.
While the majority of the experiments involving tobramycin were performed with dosing
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solutions containing 0.45% w/v NaCl (1/2NS), osmolality was varied in some investigations
by using different concentrations of sodium chloride.

IPRL Binding Studies. A dynamic dialysis method (Meyer and Guttman, 1968) was
modified to investigate solute binding or sequestration to lung tissue. Tobramycin binding
was investigated across doses (0.002, 0.004, 0.2 and 2 mg) by comparing its interaction with
lung tissue to that of mannitol (a non-binding solute). In binding studies, the IPRL preparation
was used and dosed in exactly the same way as described later for IPRL Absorption Studies.
After dosing, the isolated lung preparation was taken out of the artificial glass thorax (AGT),
sliced into 60-90 rectangular pieces (maximum linear dimension = 4mm) and transferred to a
dialysis sac (dry length: 15 cm, washed and immersed in KHS solution prior to use) with 10
mL of K4. To determine the intrinsic diffusive properties of tobramycin and mannitol in this
system, solute dialysis was also studied in the absence of lung tissue and BSA, from sacs with
identical total volumes of KHS. Sacs were closed, with minimal headspace, by ligating with
cotton thread, after which they were immersed at time zero in the perfusate reservoir
containing 200 mL magnetically-stirred receiver solution (KHS or K4) maintained at 37˚C
and pH 7.4. The solute mass enclosed in the sac at time zero (A0) was determined by
subtracting the solute lost during lung slicing (by assay of rinse solutions used in the procedure)
from the administered dose, D (determined as described in the IPRL Absorption Studies).
One mL samples were removed for assay from the receiver solution at 5, 10, and 20 minutes
after which a 100 mL samples was withdrawn at each time point of 30, 60, 90, 120, 180
minutes and hourly thereafter. An equal volume of solute-free receiver solution (37oC) was
added to replace each sampling aliquot and restore the receiver volume to 200 mL. The
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amount of solute remaining in the sac as a function of time (At) was calculated assuming mass
balance.

IPRL Absorption Studies. Use of the IPRL preparation (Figure IV.1) to study solute
absorption was carefully controlled as described previously (Byron and Niven, 1988; Sun et
al., 1999). Briefly, a rat lung was surgically removed and housed in an artificial glass thorax
(AGT) maintained at 37˚C. Krebs-Henseleit solution (KHS) with 4% (w/v) BSA was used as
perfusate (K4; 200 mL) and recirculated through the pulmonary circulation via the pulmonary
artery at a constant flow rate of 15 mL/min. A metal dosing cartridge containing 0.1 mL
dosing solution was inserted into the trachea via a tracheal cannula. A metered dose inhaler
(MDI, 25 μL drug-free CFC propellants per actuation) was connected to the dosing cartridge
and actuated once. The dosing solution was propelled into the lung as a coarse spray, and the
lung was inflated simultaneously to ~6 mL. The dosing cartridge was removed and the lung
allowed to deflate (Byron and Niven, 1988). The administered dose (to the airways of the
IPRL) was determined from the initial weight of the primed dosing cartridge, solution density
and concentration after subtracting the mass remaining in the dosing cartridge after
administration (determined by assay). The perfusate samples were taken from the well-mixed
reservoir at time zero (blank sample, immediately prior to dosing) and subsequently at 1, 3, 5,
10, 15, 20, 30, 40, 50, 60, 75, 90, 105 and 120 min following dosing. Solute concentrations
were determined as described under “Assay Methods”. Sufficient IPRL studies were
performed to yield no less than four fully viable preparations for each dosing solution, as
evidenced by the absence of any signs of edema onset over 120 min (preparations that were
“nonviable” at times < 120min were discarded). We have shown previously, and observe
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consistently with this preparation, that “signs of edema onset” occur when the (blood-free)
lungs change in outside color and texture from smooth white to a grey and/or patchy
appearance; this appearance change is an early indicator of the preparation’s declining
viability, shortly after which values for the wet lung/dry lung weight ratio, epithelial
permeability to solutes and other effects change markedly (Byron et al., 1986; Niven et al.,
1990). At the end of each IPRL absorption study, the lung tissues were collected, homogenized
and assayed for solute remaining in both the airways and the lung tissue.

Assay Methods. [3H]Tobramycin and [3H]mannitol concentrations were determined by
scintillation counting relative to standards prepared freshly for each experiment (Liquid
Scintillation Analyzer, Tri-Carb 2800-TR, PerkinElmer Life and Analytical Sciences) after
first validating the radioactivity assay for tobramycin with high performance liquid
chromatography–mass spectrometry (HPLC-MS) to ensure that chemical degradation and/or
metabolism did not occur in lung tissue or perfusate over the duration of a typical experiment
(see Appendix III and IV). In brief, perfusate samples containing radiolabeled solutes were
used neat or diluted in K4. One milliliter aliquots were added to 5 mL scintillation cocktail
(Ecoscint XR; National Diagnostics) in 7-mL polypropylene scintillation vials and well mixed.
Total radioactivity was expressed as disintegrations per minute. Disintegrations per minute
from accurately prepared [3H]tobramycin or [3H]mannitol standard solutions in K4 were
measured independently for each assay series in order to calculate solute concentrations in
unknown test solutions. Fluorescein concentrations in perfusate were assayed by
spectrofluorophotometer (RF-5301 PC, Shimazu Corporation, Kyoto, Japan; λex and λem = 490
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and 520 nm, respectively), as described earlier (Byron and Niven, 1988; Byron et al., 1986;
Sakagami et al., 2002).

Data analysis. Kinetic Analysis was performed according to the theory described above
and Schemes IV.1-3. The data from IPRL binding studies using dynamic dialysis were
expressed in accord with Scheme IV.3, as the fraction of the solute dose (At/A0) remaining in
the sac as a function of time. The ke value for tobramycin was first determined by studying its
dialysis kinetics in the absence of IPRL components (tissue and protein). In this case, linear
regression analysis of the first-order data for ln [At/A0] versus t was performed to determine
its value (Meyer and Guttman, 1968). The binding rate constants, in the presence of lung tissue,
k12' and k21', were then determined by fitting data for [At/A0] versus t to eq. IV.3 by least mean
square non-linear regression analysis. The value for ke was fixed, whereas k12' and k21' were
allowed to float. Goodness-of-fit was assessed using the calculated r2 and model selection
criterion (MSC) by Scientist 3.0 (MicroMath Scientific Software, Salt Lake City, UT). Data
from IPRL Absorption Studies were grouped in accord with the nominal dose initially added
to the dosing cartridge. Each nominal dose resulted in a mean value for D (Scheme IV.1), due
to solution retention in the cartridge. Fluorescein absorption into perfusate was expressed as
the mean fraction of each administered dose reaching the perfusate, Fp, versus time. Best
estimates for fluorescein’s mean absorbable fraction, Fa (=A0/D; Scheme IV.1) and its
apparent first-order rate constant for absorption, ka, were obtained by fitting the unweighted
data for Fp versus time to eq. IV.1 using Scientist 3.0. Because fluorescein that penetrates the
airways proximal to the circulating perfusate is known to be completely absorbed, this
provided a mean value for the solute’s eventually absorbable fraction, Fa that could be used
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across solutes. Tobramycin data was analyzed according to Scheme IV.2, where best estimates
for the rate constants describing binding and absorption (k12, k21, ka) at different nominal doses
were determined by curve-fitting tobramycin Fp (fraction of administered dose in perfusate)
versus time data to eq. IV.2.

IV.c RESULTS

IPRL Binding Studies. Tobramycin dialysis from the sac is shown as mean At /A0
(fraction of administered dose remaining in the sac) versus time in Figure IV.2A. Biphasic
(biexponential) profiles resulted from experiments in which drug release from sliced lung
tissue occurred after airway dosing to the IPRL at five different dose levels; smaller doses
showed greater values for tissue retention with time. In the absence of lung tissue, control
experiments showed mono-exponential (apparent first-order) release of tobramycin from the
dialysis sac under sink conditions (Meyer and Guttman, 1968). Following the data analysis,
the mean dialysis rate constant, ke (Scheme IV.3), for tobramycin was found to be doseindependent (0.0107±0.0021min-1; Figure IV.2A). Mannitol, a nonbinding solute, produced
monoexponential and dose-independent At /A0 profiles in the presence and absence of IPRL
tissue (Figure IV.2B). Tobramycin dialysis data from IPRL tissue (Figure. IV.2A) was fitted
to eq. IV.3 to produce the best estimates of the rate constants in Scheme IV.3. These are shown
in Table IV.1 for each dose; dashed curves in Figure IV.2A were produced by simulation
using the rate constant values shown in the table. Tobramycin’s dissociation rate constant (k21')
was effectively dose-independent, whereas k12' appeared saturable and decreased with
ascending dose.
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Figure IV.2. Mean fraction of solute remaining in the dialysis sac, At/A0, versus time. (A)
Tobramycin at different nominal doses. Dashed lines show the best fits to eq. IV.3. Error
bars are sample SDs (n≥3). , 0.002 mg; , 0.004 mg; , 0.2 mg; , 2 mg; ,10 mg; ,
control (tobramycin 2 mg and 0.002 mg in absence of IPRL). (B) Mannitol at two nominal
doses. , 0.02 mg; , 2 mg; , control, (0.02 mg of mannitol in absence of IPRL).
Table IV.1: Best estimates (95% CI) of tissue binding/sequestration rate constants in Scheme
IV.3 (eq. IV.3) from dynamic dialysis alongside the coefficient of determination, r2, and “model
selection criterion” (MSC).
The value of ke was fixed at 0.0107 min-1, its value in the absence of lung tissue.
Dose
mg

k12'
min-1

k21'
min-1

k12'/k21'

r2

MSC

0.002

0.0174 (0.0160-0.0189)

0.0041 (0.0033-0.0048)

4.29

0.9999

5.74

0.004

0.0112 (0.0099-0.0124)

0.0037 (0.0027-0.0046)

3.02

0.9998

5.70

0.2

0.0094 (0.0087-0.0100)

0.0043 (0.0037-0.0050)

2.17

0.9999

7.03

2

0.0070 (0.0060-0.0080)

0.0038 (0.0025-0.0051)

1.83

0.9997

5.89

10

0.0052 (0.0031-0.0074)

0.0039 (0.0033-0.0045)

1.3.

0.9982

4.29
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IPRL Absorption Studies. Fp versus time data for fluorescein (Figure IV.3) was fitted to eq.
IV.1 to obtain best estimates of the absorbable fraction (Fa) and the first-order rate constant for
absorption (ka) for this nonbinding solute; the values were 0.75 and 0.076 min-1, respectively
(Table IV.2). Although mannitol absorption was too slow to reach an asymptote within the IPRL’s
viable lifetime (Sun et al, 1999), its ka values shown in Table IV.2 were derived by fitting mannitol
data to eq. IV.1 assuming that the absorbable fraction, Fa, was the same as that of fluorescein (Fa
= 0.75). While that assumption may not be completely accurate, the approach was supported by
the absence of a statistical difference between mannitol’s Fp (fraction of administered dose in
perfusate) versus time profiles at different nominal doses (0.02 and 2 mg; t-test, p < 0.05; data not
shown) and the agreement of ka values (Table IV.2) with reports in the literature for mannitol in
the in situ rat lung where absorption half lives were derived by measuring solute disappearance
from the lung (Brown and Schanker, 1983). In contrast to fluorescein and mannitol, tobramycin’s
absorption was clearly dose-dependent, the rate and extent of its pulmonary absorption increasing
with the magnitude of the administered dose (Figure IV.3). At 120 minutes following tobramycin
administration, the values for mean Fp (± SD; nominal dose) were 0.449 (± 0.024; 0.002 mg);
0.505 (± 0.021; 0.02 mg); 0.587 (± 0.028; 0.2 mg) and 0.612 (±0.050; 2 mg). Tobramycin’s Fp
versus time data showed good agreement with Scheme IV.2 and eq. IV.2, as indicated by the
continuous curves shown in Figure IV.3. Best estimates of the rate constants used to generate these
curves are reported in Table IV.2 alongside the values for the coefficient of determination, r2, and
the model selection criterion (MSC). The rate constant for absorption appeared to be doseindependent (range from 0.065 to 0.070 min-1) and close to that of fluorescein (0.076 min-1). The
rate constant for dissociation from intact IPRL tissue (k21) was also relatively constant (0.0180.022 min-1), while that for association (k12) decreased from 0.164 to 0.072 min-1 with increasing
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airway dose from 0.002 to 2 mg. As a result, the ratio of k12/ k21 decreased from 8.9 to 3.4 when
the nominal dose was increased from 0.002 to 2 mg.

0.8
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0.5
0.4
0.3
0.2
0.1
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0

30

60
Time (minutes)

90

120

Figure IV.3. Mean Fp = mean (±SD) fraction of administered dose (D) transferred to the
perfusate versus time for fluorescein (nominal dose: 0.02 mg; open symbols) and
tobramycin (closed symbols) in the IPRL. Nominal doses were 0.002 (; n=6); 0.02mg (;
n=5); 0.2mg (; n=5) and 2mg (; n=4). Solid curves are the best fits for all profiles to eq.
IV.1 (fluorescein) and eq. IV.2 (tobramycin) based on Schemes IV.1 and 2, respectively. Fa,
the absorbable fraction of the administered dose, was fixed at 0.75, whereas ka, k12, and k21
were allowed to float to produce the best estimates shown in Table IV.2.
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Table IV.2. Estimated parameters (95% CI) and goodness-of-fit for different solutes in
accord with Scheme IV.1 (fluorescein and mannitol) and Scheme IV.2 (tobramycin) in the
IPRL Absorption Studies with Fa = 0.75.
Blank cells for k12 and k21 indicate data consistent with Scheme IV.1.
Dose
mg

ka
min-1

k12
min-1

k21
min-1

0.002

0.0651
(0.0150-0.0852)
0.066
(0.0572-0.0748)
0.0695
(0.0610-0.0781)
0.07
(0.0626-0.0774)
0.0184
(0.0154-0.0213)
0.0198
(0.0180-0.0216)
0.0761
(0.0694-0.0828)

0.1639
(0.0970-0.2308)
0.1307
(0.1226-0.1388)
0.0905
(0.0714-0.1097)
0.0721
(0.0575-0.0867)

0.0184
(0.0161-0.0207)
0.0205
(0.0184-0.0225)
0.0223
(0.0199-0.0246)
0.0214
(0.0189-0.0239)

0.02
Tobramycin
0.2
2
0.02
Mannitol
2
Fluorescein

0.02

k12/k21

r2

MSC

8.91

0.9998

6.04

6.38

0.9998

6.06

4.06

0.9999

6.89

3.37

0.9999

6.82

0.9896

2.25

0.995

3.45

0.9988

4.8

IV.d Discussion

Binding of tobramycin and other aminoglycosides to various tissues has been used to
explain the formation of deep compartments in pharmacokinetic studies ” (Mingeot-Leclercq
and Tulkens, 1999; Nagai and Takano, 2004; Stepanyan et al., 2011), some epithelial cells of
which (e.g. kidney proximal tubule and inner ear hair cells) are associated with nephro- and
ototoxicity (Hiel et al., 1993; Just and Habermann, 1977; Nagai and Takano, 2004; Todd and
Hottendorf, 1995). It is noteworthy, and probably because of the physiologic existence of
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these drugs as polycations, transfer into cells is slow and intracellular sequestration can be
persistent. In the hope of elucidating the drug’s binding to and/or intracellular sequestration
by lung tissue, dynamic dialysis was performed both in the presence and absence of tissue,
and from the sliced IPRL, after dosing the airways using the same technique as that used for
IPRL absorption studies. The open circles in Figure IV.2A show the apparent first-order, doseindependent dialysis of tobramycin in the absence of lung tissue in which there was no
evidence of drug binding. The comparator data shown in Figure IV.2B, for the nonbinding
solute mannitol, was monoexponential and dose-independent (r2 >0.98) both in the presence
and absence of tissue, indicating only that the presence of sliced lung tissue slightly reduced
the value of ke for diffusive release from the sac (Scheme IV.3; ke for mannitol = 0.025 and
0.019 min-1 in the absence and presence of sliced IPRL tissue, respectively) by hindering
diffusion. Most notably, the tobramycin data for At /A0 (fraction of administered dose
remaining in the sac) versus time at different doses in the presence of lung tissue were
described well by eq. IV.3 and Scheme IV.3 (r2>0.998) showing clear evidence of dosedependent lung tissue binding or sequestration, as summarized by the decreasing values for
the forward binding rate constant, k12' and the ratio k12'/k21' as doses were increased (Scheme
IV.3, Table IV.1). While the model described in Scheme IV.3 assumes that tissue binding is
zero at t=0 (and in practice, some binding must have occurred during the short period used for
tissue slicing and dialysis set-up), these values for k12' and k21' implied that tissue binding
occurred relatively slowly after airway administration and that all three rate constants in
Scheme IV.3 had a similar order of magnitude. Efforts to determine whether significant
binding/sequestration was due to tissue or the constituents of the IPRL airway lining fluid
implied that lung tissues themselves were largely responsible for antibiotic sequestration.
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Bronchoalveolar lavage samples; diluted with KHS containing low tobramycin concentrations
(consistent with doses of approximately 0.002 mg) showed no difference in drug dialysis
kinetics from the IPRL tissue-free control data for At/A0 in Figure IV.2A.

This “slow-on” and “slow-off” binding behavior seen during dynamic dialysis supported
the kinetic analysis of Fp versus time data in IPRL absorption studies. When the ex vivo IPRL
was used, the values of the aminoglycoside’s binding constants in Scheme IV.2 (Table IV.2)
were quantitatively different to those from the dialysis experiments (association and
dissociation occurred faster under conditions involving absorption into perfusate), although
the overall trend in the rate constant values was the same as that seen during dialysis. Neither
fluorescein nor mannitol showed dose-dependent binding behavior and both showed
monoexponential absorption properties (ka and Fa values) consistent with reports in the
literature (Brown and Schanker, 1983; Byron and Niven, 1988). Tobramycin, however,
showed decreasing rates of fractional absorption (transfer from airways to perfusate) as a
function of decreasing dose and increasing binding/sequestration. Notably, dosing solution
osmolality appeared to have no effect on Fp versus time data. For example, Fp at 120 min for
a tobramycin dose at 0.2 mg in 0.9% w/v NaCl showed no statistical difference to that from
0.2 mg in 0.45% w/v NaCl (t test, P < 0.05). However, the data for Fp versus time at different
doses were described well by eq. IV.2 and Scheme IV.2 (r2>0.998) with clear evidence of
dose-dependent and possibly saturable lung tissue binding summarized by the decreasing
values for the forward binding rate constant, k12 and the ratio k12/k21 as doses were increased
(Table IV.2). The significant difference between the retention of this solute in lung tissue was
related to tobramycin’s slow binding or sequestration following its administration. Values for
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k21 appeared unrelated to dose, but values of k12 decreased as the dose was increased, but
without evidence of capacity limitation. While the exposure of different tissue sites was
clearly possible for absorption and dialysis experiments (IPRL was sliced immediately
following dosing), the trend in the data for the lung tissue binding or sequestration constant,
k12 (increases with decreasing dose) and k21 (effectively dose-independent), was consistent
with the rate constant data for the sliced IPRL.

To the best of our knowledge, this is the first work to investigate tobramycin binding to
and/or sequestration by lung tissue and explore its effects on the drug’s pulmonary disposition
following airway administration. Dynamic dialysis, initially used for protein binding studies,
was successfully employed to study tissue binding and sequestration, and the results were
consistent with those from the realistic ex vivo IPRL model. Based on the results, it was
possible to calculate the apparent elimination half-life from the IPRL (equal to 0.693/β; eq.
IV.2) as 2.3, 1.8, 1.3 and 1.2 hours for nominal doses of 0.002, 0.02, 0.2 and 2 mg, respectively.
Notably, if binding did not occur, absorption into the perfusate (and thus, elimination from
the IPRL) should occur with a half-life of a ~10 minutes (0.693/ka; Table IV.2), similar to that
for fluorescein anions (Niven and Byron, 1988; Table IV.2). The 1.8-hour half-life at a
nominal dose of 0.02 mg is consistent with the in vivo lung elimination half-life of 2.1 hours
reported by Valcke and Pauwels (1991) in rat alveolar lining fluid following aerosol
administration of a similar dose .

In clinical treatment of humans, tobramycin inhalation solution (TOBI®; Novartis, Basel,
Switzerland), the commercial nebulizer formulation used for cystic fibrosis patients, is
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prescribed as an intermittent (28 days on/28 days off) treatment with 300 mg/5 mL nebulized
and inhaled twice daily regardless of age (≥6 yrs) or body weight. Since the percentage of
each nebulizer dose reaching the lung via the recommended PARI LC PLUS nebulizer has
been reported to be ~15% (Lenney et al., 2011), a lung dose of ~45 mg could be expected in
a 70-kg human. Based on weight scaling, this corresponds approximately to a nominal dose
of approximately 0.2 mg to the airways of the rat lungs used in the IPRL studies described
here, where the k12/k21 ratio was 4.06 (Table IV.2). Although species differences may well
exist, similar cell constituents and concordance with alveolar surface area, lung volume,
capillary volume and body weight have been reported across many species, including rats and
humans (Crapo et al., 1983; Cryan et al., 2007; Plopper, 1983). Therefore, in conclusion, these
studies in rat lung appear to support the existence of tobramycin retention in lung tissue
following airway administration at doses likely to produce airway concentrations seen in
humans. As a result of this slow-on and slow-off tissue binding or sequestration, the
antibiotic’s longevity in the lung is extended. It is possible that this may account, at least in
part, for the apparent success of tobramycin inhalation therapy seen in clinical practice.
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Chapter V
THE EFFECTS OF OSMOLALITY, pH AND TOBRAMYCIN CONCENTRATION OF
DOSING SOLUTIONS ON AIRWAY EPITHELIAL INTEGRITY IN THE RAT LUNG
FOLLOWING AIRWAY ADMINISTRATION

V.a INTRODUCTION

Pharmaceutical formulators often aim to make solutions for inhalation isotonic with blood and
neutral with respect to pH. In practice, they frequently compromise these “targets”, but need to
observe certain limits for osmolality and pH deviations to avoid issues associated with airway
irritation and potential pulmonary epithelial damage (Weber et al., 1997). Administration of nonisotonic and non-physiologic pH solutions to the airways of sensitive individuals has been reported
to cause cough, bronchoconstriction, airway hyperactivity, or bronchospasm (Eschenbacher et al.,
1984; Godden et al., 1986) and the occurrence of such airway reactions has sometimes been
associated with alterations in pulmonary epithelial integrity, evidenced by an increase of
intercellular space and the opening of tight junctions (Ohashi et al., 1992); this can lead to increases
in airway epithelial permeation to solutes that diffuse via paracellular pathways, such as mannitol
and

99m

Tc-DTPA (technetium-99 m-labelled diethylene triamine pentaacetic acid) (Wan et al.,

2000; Wells et al., 1994).
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Aminoglycosides and other polycations in certain concentration ranges have also been reported
to affect the integrity of various epithelia, including the airways, as manifested by increases in
epithelial permeation and damage caused by the cytotoxicity of these compounds in vivo and in
vitro (Dong et al., 2011; Florea et al., 2006; Karasawa and Steyger, 2011; Nagai and Takano, 2004;
Schipper et al., 2000; Seki et al., 2008). As to aminoglycosides specifically, this class of drugs in
certain concentration ranges has been reported to affect the permeation of vestibular epithelia and
proximal tubular epithelia, and also could cause cell apoptosis and necrosis due to high local
concentrations seen in studies of drug-induced oto- and nephro-toxicity (Karasawa and Steyger,
2011; Kim et al., 2005; Todd et al., 1994).

As all these factors may also perturb tobramycin’s disposition following airway administration,
the IPRL studies in this chapter were aimed to validate tobramycin’s disposition model in the IPRL
described in Chapter IV, or at least to define the boundaries of its applicability; this by planning
and executing a series of experiments designed to eliminate alternate perturbation possibilities that
could interfere with the binding models described earlier.

V.b MATERIALS AND METHODS

IPRL Absorption Studies were performed using materials and general methods identical to
those described in detail in Chapter IV of this thesis. Only the dosing solutions that were used for
administration to the airways differed with respect to their formulation. Two separate series of
IPRL Absorption Studies were performed in which the effects of realistic, but minor, variations
in (i) dosing solution osmolality and (ii) dosing solution pH were studied. In a separate
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experimental arm (iii) the effects of tobramycin concentration on mannitol’s absorption were
investigated. For each dosing solution, no less than four fully viable preparations were studied and,
as before, the absorption results from each group (n≥4) were expressed as mean cumulative
fraction of the administered dose absorbed into the perfusate, Fp, versus time.
(i) [3H] tobramycin dosing solutions at 2 mg/mL were prepared in 0.225 % or 0.9 % w/v NaCl
and adjusted to pH 7.4 with H2SO4. The osmolality of these tobramycin dosing solutions and their
2 mg/mL tobramycin counterparts described in Chapter IV (in which the vehicle was 0.45% w/v
NaCl) were determined using the freezing point depression method using an Advanced® Model
3320 Micro-Osmometer (Advanced Instruments, Inc., Norwood, MA), to measure and report the
apparent osmolality of these solutions. Tobramycin absorption data obtained from these dosing
solutions in 0.225 % and 0.9 % w/v NaCl were compared to the control data shown in Chapter IV,
in which the same dose of tobramycin was administered in 0.45% w/v NaCl at pH 7.4.
(ii) To elucidate the effects of pH of the dosing solution on tobramycin absorption, [3H]
tobramycin dosing solutions at 2 mg/mL were prepared in 0.45% w/v NaCl and adjusted to pH 4.6
or 8.6 with H2SO4 when necessary (pH of 2 mg/mL solutions of the base was ≥ 8.6). The absorption
of tobramycin from these solutions was determined and compared to the control data at the same
nominal tobramycin lung dose and pH 7.4 reported in Chapter IV.
(iii) The effects of tobramycin concentration on mannitol absorption were investigated by
studying the absorption of [3H] mannitol from dosing solutions containing 0.2 mg/mL mannitol
in 0.45% w/v NaCl and pH 7.4 to which tobramycin (non-labeled) was added at 2, 20 and 60
mg/mL. Mannitol’s absorption after its co-administration with these different tobramycin doses
was investigated and compared to that of mannitol in the absence of tobramycin .
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Statistical analysis A repeated measures analysis of variance (ANOVA) was used to model
mean tobramycin absorption as a function of time separately for each dosing solution (e.g. with
different values of osmolality and pH), and compare the drug’s absorption within different dosing
solutions for each evaluation as described in Methods. The model included fixed effects for time,
dosing solution, interaction between dosing solution and time, and a random effect by subject or
IPRL preparation. A Bonferroni multiple comparison procedure was used to adjust the overall
significance level with α = 0.05.

V.c RESULTS AND DISCUSSION

As described in the conclusion to Chapter IV, and because the percentage of nebulizer doses
likely to reach the lung from the recommended PARI LC PLUS nebulizer is ~15% (Lenney et al.,
2011), a lung dose of ~45 mg would be expected in a 70-kg human inhaling TOBI, in accord with
the manufacturer’s instructions, twice daily (TOBI is formulated at 60mg/mL in 1/4 Normal Saline
(NS) or 0.225% w/v NaCl). The experiments in this thesis using the IPRL were designed to bracket
the likely doses (and thereby airway surface concentrations) seen in humans, based on weight
scaling, where a lung dose of 45mg corresponds approximately to 0.2 mg in the airways of the rat
lungs used here. The justification for this approach was based on the literature in which similar
cell constituents and concordance with alveolar surface area, lung volume, capillary volume and
body weight have been reported across species, including rats and humans (Crapo et al., 1983;
Cryan et al., 2007; Plopper, 1983). The experiments described in this chapter in which the effects
of pH and osmolality were evaluated were focused therefore on a single nominal dose of 0.2 mg
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delivered to the airways by intratracheal administration of 2 mg/mL tobramycin in a 0.1 mL coarse
spray of solution in different vehicles.

Effects of dosing solution osmolality on tobramycin absorption
Table V.1 shows the experimentally determined osmolality values of tobramycin solutions
prepared in 0.225, 0.45 or 0.9 %w/v NaCl. The absorption data for tobramycin at a nominal 0.2
mg dose are shown, expressed as Fp as a function of time, from either highly hypotonic (80
mOsmol/kg) through isotonic (298 mOsmol/kg) dosing solutions in Figure V.1.

Table V.1 Osmolality of tobramycin solutions at different concentrations at pH 7.4 (±0.2) prepared
in 0.9% (normal saline, NS), 0.45% (1/2 NS) or 0.225% w/v NaCl (1/4 NS) solution.
Tobramycin concentration
mg/mL
mmol/L
0
0
0.02
0.04
0.2
0.4
2
4.3
2
4.3
2
4.3
20
42.8
60
128.5
100
214.1

Vehicle
1/2NS
1/2NS
1/2NS
1/2NS
NS
1/4 NS
1/2NS
1/2NS
1/2NS
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mOsmol/kg
150
151
150
157
298
80
195
257
330

Figure V.1 Mean cumulative fraction of administered dose versus time following administration
of tobramycin in vehicles with different osmolality. Tobramycin dosing solutions used in these
experiments contained 2 mg/mL tobramycin at pH 7.4 in 0.9 % (normal saline, NS), 0.45% (1/2
NS), and 0.225% w/v NaCl (1/4 NS). Error bars are sample standard deviation (n=4 or 5).
The osmolality of the dosing solutions that were studied appear to be representative of the range
used in clinical practice. The absorption data show clearly that no statistical difference in
absorption kinetics was detectable in the IPRL throughout the 2 h period of an IPRL experiment
(p value > 0.0035) due to changing osmolality. Accordingly, the results imply that these changes
in osmolality do not affect the modeling and interpretation of the drug’s disposition that are
discussed in detail in Chapter IV. Furthermore, the results also indicate that for even these
significant volumetric additions of solution to the epithelial surfaces of the lung (0.1 mL in a 300
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g rat lung) failed to disturb the epithelial barrier sufficiently to change the absorption of the
aminoglycoside.

The values for osmolality that were measured are worthy of some further explanation however.
The theoretical osmolality of 0.9%w/v NaCl (Normal saline or NS) is close to 300 mOsmol/kg
(Sinko, 2006). The value seen in Table V.1 for the 2mg/mL tobramycin solution in NS is consistent
with this value and shows the minimal contribution of the aminoglycoside to the overall osmolality
at the concentrations used for the absorption studies (in which the contribution of tobramycin (≤2
mg/mL or 4.3 mmol/L) was small). It is not until tobramycin concentrations reached and exceeded
20mg/mL in 0.45% w/v NaCl, that a significant increase of osmolality was seen due to the drug
itself; drug contributions of 45, 107, and 180 mOsmol/kg were calculated for concentrations at 20,
60 and 100 mg/mL, respectively, by subtracting the osmolality contributed by the vehicle (150 for
0.45% w/v NaCl) from the total osmolality of these solutions shown in Table V.1.

Theoretically, at pH 7.4, tobramycin is expected to have around 2.5-3 positive charges based
on the reported pKas for its amino groups and according to acid-base equilibrium theory (Szilagyi
et al., 1993). If the number of charges per tobramycin molecule at pH 7.4 is equal to 2.5, there
should also be an increase in osmolality due to the addition of sulfate ion concentration needed to
bring about the pH adjustment to a value of 7.4. Theoretically therefore, ignoring the contributions
of NaCl and assuming complete dissociation of tobramycin and sulfate ions in solution, the
osmolality of part-neutralized tobramycin at 20, 60, and 100 mg/mL, should be close to 95, 289
and 482 Osmol/kg, respectively, assuming that the density of these solutions was not significantly
changed from that of water. The measured smaller osmolalities shown in Table V.1, due to the
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tobramycin and sulfuric acid in the higher concentration pH 7.4 solutions, imply significant nonideality, perhaps due to ionic interactions, in the solutions containing 20, 60 and 100mg/mL (the
theoretical osmolality of a 100mg/mL tobramycin solution in ½ NS at pH 7.4 is expected to be ~
632 mOsm/kg in the event of complete ionic dissociation). Notably however, these non-ideal
results shown in Table V.1 for high concentration tobramycin solutions are consistent with the
reported osmolalities for Tobramycin Solution for Inhalation (60mg/mL) in the monograph in
United States Pharmacopoeia (USP), where the drug solution in ¼ NS should lie in the range 150200 mOsm/kg (USP29-NF24: http://www.pharmacopeia.cn/v29240/usp29nf24s0_m83766.html)
and the experimentally determined osmolality values for tobramycin solutions at 40 and 80 mg/mL
in sterile water, ½ NS or NS at neutral pH according to Law (Law, 2001).

These large differences in osmolality that are seen between the experimental measurements and
the theoretical calculations for tobramycin imply the existence of strong interionic interactions in
solution. In an attempt to quantitatively assess this phenomenon, the practical osmotic coefficient
of tobramycin, g, as a measurement of the drug’s dissociation, was estimated to be 0.47, 0.37 and
0.37 for tobramycin concentration at 20, 60, and 100 mg/mL at pH 7.4, respectively, using the
equation eq. V.1 (Sinko, 2006):
eq. V.1

∗

where

refers to the contribution of osmolality by tobramycin as an electrolyte;

v is the number of ions into which an electrolyte dissociates (a value of 2.25 for tobramycin sulfate
was used, corresponding to 2.5 charges associated with tobramycin molecules in pH 7.4); m refers
to the electrolyte molality and is assumed to be equal to the value of molarity, assuming the density
of these solutions was not effectively changed from that of water.
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Values of g ≤ 0.5 imply that tobramycin sulfate behaves as less than half of the total ions into
which tobramycin sulfate theoretically dissociates in solution. Although it is difficult to understand
this atypical electrolyte behavior and the mechanisms responsible for it, this uncommon colligative
characteristic of tobramycin clearly shows the uniqueness of this compound as a polyvalent
electrolyte.

In the literature, it has been suggested that a solution for inhalation should have an osmolality
between 150 and 550 mOsm/kg (Weber et al., 1997). Others have reported that administration of
non-isotonic solutions to the lungs via inhalation in the clinic are acceptable, even though such
administrations may produce bronchial reactions manifested by cough, bronchoconstriction,
airway hyperreactivity, or bronchospasm in some individuals (Eschenbacher et al., 1984; Weber
et al., 1997). The effect of hypotonic solutions on the airway permeability of

99m

Tc-DTPA was

evaluated by Wells et al. (Wells et al., 1994) who were able to show that enhanced airway
permeation could be detected across isolated sheep trachea when the tracheal lumen was filled
with hyposmolar fluid (128 mOsmol/kg). Based on the results shown in Figure V.1, Wells’
findings do not appear to be relevant to the absorption of tobramycin from the airways of the rat
lung.

Effects of dosing solution pH on tobramycin absorption
Mean cumulative fraction of administered dose absorbed into the perfusate, Fp, from dosing
solutions of different pH are shown as function of time in Figure V.2. Tobramycin dosing solutions
were prepared at the same drug concentration, 2 mg/mL, but adjusted to three different pH values
with the addition of sulfuric acid: values of pH = 4.6, 7.4 and 8.6, believed to be representative of
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the range used in clinical practice. Statistically, administration of tobramycin under these
conditions showed no alteration in the drug’s absorption kinetics when compared to the control (p
value > 0.0035). It was noteworthy that administration of these basic or acidic dosing solutions to
the IPRL airways appeared to have no effect on the isolated rat lung’s viability (no edema was
observed during the typical 2 hours’ experiment period), and thus, it was probable that these pH
values and the addition of solutions as coarse sprays failed to disrupt the epithelial integrity of the
airways of the IPRL. Because the pH values that were chosen should affect the degree of ionization
of the aminoglycoside, the results also implied that the modified ionization status of the amino
groups in each tobramycin dosing solution had no effect on the drug’s absorption, binding or
sequestration at this (realistic) dose and airway surface concentration. This could of course, simply
be an indication that the buffering power of the organ and its circulating perfusate simply
overwhelms the addition of a pH-modified solution bolus containing 2mg/mL tobramycin.
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Figure V.2 Mean cumulative fraction of administered dose versus time, Fp, for tobramycin dosed
at 0.2mg using 0.1mL of 2mg/mL solutions in 0.45% w/v NaCl at either pH 8.6, 7.4 or 4.6. Error
bars are sample standard deviations (n=4 or 5).

Effect of tobramycin concentration on mannitol absorption
The absorption of the hydrophilic monosaccharide mannitol and/or its permeation rate through
epithelial membranes is believed to be a measure of simple diffusion through hydrophilic “pores”
or passive paracellular transport. In short, the solute is believed to be a marker for the integrity of
tight junctions and the “leakiness” of epithelial monolayers such as those seen in the airways of
the lung (Wan et al., 2000). Mannitol absorption data, therefore, should be usable as a surrogate
measure of epithelial integrity in a preparation such as the IPRL; factors that accelerate its
absorption, perhaps alter the barrier separating (in the IPRL) the airways from the perfusate. The
results of IPRL absorption studies following airway administration of mannitol alone or its co71

administration with unlabeled tobramycin in different concentrations, are shown in Figure V.3.
The nominal lung dose of mannitol in all these IPRL studies was held constant at 0.02 mg/rat lung
(0.2 mg/mL in a fixed solution volume of 0.1 mL). Quite clearly, co-administration 0.2 mg
tobramycin with mannitol, failed to bring about alterations in mannitol absorption profiles (mean
Fp versus time) when these were compared to the tobramycin-free control data (p value > 0.0035;
Figure V.3). At the high dose extremes however, where tobramycin concentrations were 60 mg/mL
or greater (nominal doses of 6mg or more), the disruptive effect of tobramycin on airway epithelial
integrity could be seen clearly as a major accelerant for mannitol absorption in the IPRL (p value
< 0.0035; Figure V.3). Notably, also at this dose, among a total of 7 rat lungs that were used for
this experimental condition, only 4/7 showed a lack of edema over the 120 minute study; three rat
lungs became edematous within one hour of dosing. This decrease in viability appeared to be due
to the presence of high tobramycin concentration in the airway lumen, a conclusion that was
supported by an attempt to investigate tobramycin’s absorption at a dose of 10 mg where edema
was observed in all IPRL preparations within one hour of dosing. These observations implied that
the values for Fp versus time at the 6 mg dose were actually an underestimate of the true values,
due to the obligatory discard of non-viable preparations.

The tobramycin dose effect on mannitol absorption can also be seen, both in Figure V.3 and
Table V.2, where values for Fp were compared to the tobramycin-free control at identical sample
times and show that the effect begins to be manifested even at doses as low as 2 mg (0.1 mL,
tobramycin concentration = 20 mg/mL), when both mannitol and tobramycin were administered
in the same solution (p value < 0.0035). Although there was no observation this co-administration
affected the isolated rat lungs’ viability as seen from a higher tobramycin dose of 2 mg, it is
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possible that this dose level of tobramycin in the dosing solution could cause a certain degree of
membrane disruption such as the cleavage of tight junctions and accelerated mannitol’s absorption.

Figure V.3 Mean cumulative fraction of administered mannitol dose versus time. The closed
circles refers to the mean Fp data from the administration of 0.02 mg mannitol alone, while the
open symbols refer to the data from the co-administration of 0.02 mg mannitol with tobramycin at
different doses. * indicates that the mean values of Fp were calculated from 4 out of 7 rat lungs,
by discarding the results from the isolated rat lungs in which edema occurred during the 2 hr’s
experiment period.
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Table V.2 The increase in mean Fp for mannitol with time seen due to co-administration with 2
or 6 mg tobramycin to the airways of the IPRL.
Δ Fp
(Fp,coadministration- Fp,control)#
2 mg
6 mg
Time (min)
1
-0.007
0.028
3
0.023*
0.125*
5
0.061*
0.176*
10
0.094*
0.245*
15
0.118*
0.260*
20
0.107*
0.242*
30
0.119*
0.241*
40
0.115*
0.221*
50
0.115*
0.203*
60
0.119*
0.183*
75
0.093*
0.144*
90
0.103*
0.139*
105
0.058
0.082
120
0.040
0.059
# control data for Fp was taken from the results of administration of mannitol alone at a lung
dose of 0.02 mg. Statistical significance is shown as * (p value <0.0035).

V.d CONCLUSIONS

Osmolality and pH variations in airway dosing solutions in the range 80 through 298
mOsmol/kg and 4.6 to 8.6, respectively, failed to alter the rate or extent of tobramycin transfer to
perfusate following airway administration to the IPRL in doses designed to produce airway
concentrations typical of those used clinically. These experiments, that were referenced in the text
of Chapter IV, are thought to be useful adjuncts to the data showing that aminoglycoside
disposition following inhalation at clinically relevant doses is unlikely to be influenced
significantly by small changes in formulation variables such as NaCl content and pH; there was
no evidence that these changes affected the epithelial integrity of the IPRL. Tobramycin itself
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however, was implicated as an agent capable of epithelial damage, when its effects were studied
by co-administration with mannitol. To our knowledge, this is the first report of the effect of
aminoglycosides on airway epithelial integrity. Based on the results however, drug induced
epithelial changes are expected to be minimal at lung doses seen for the clinical treatment of
humans.

Tobramycin’s membrane damaging effects were clearly dose and concentration dependent
however, and may begin to be seen at IPRL doses as low as 2 mg. While these experiments differed
from those described in Chapter IV and involved mannitol administration in the same solution as
the aminoglycoside, the slight elevation in the reported values for tobramycin’s ka with dose (Table
IV.2) may have been due in part to the drug’s membrane toxicity. It is impossible to say whether
this latter observation has any clinical significance, especially given the fact that the drug is mostly
used to treat individuals with CF who have abnormal airway epithelia in the first place and the
treatment of their infections is a clinical imperative. Overall, these findings appear to eliminate the
possibilities that significant airway perturbations other than tissue binding and sequestration are
responsible for the drug’s pulmonary pharmacokinetics, and that it is those phenomena that bring
about the drug’s prolonged presence in the lung following airway administration.
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Chapter VI
SUMMARY AND CONCLUSIONS

Nebulized tobramycin therapy has improved the health and well-being of many cystic fibrosis
(CF) patients in spite of its pulmonary disposition being poorly understood. In this dissertation, a
meta-analysis of the pharmacokinetic (PK) data in humans is described as a precursor to systematic
series of experimental investigations using the isolated perfused rat lung preparation (IPRL). In an
attempt to elucidate both the kinetics and extent of pulmonary absorption in humans, the
bioavailability of inhaled tobramycin in healthy and CF adults was re-evaluated in Chapter III
using both non-compartmental and compartmental approaches partnered with the drug’s intrinsic
PK parameters obtained from intravenous (IV) studies in the literature. This work revealed that in
both CF and healthy adults, tobramycin absorption from the lung following inhalation was more
complete than is commonly assumed based on the drug’s theoretical behavior as an
aminoglycoside poly-cation at physiologic pH (Szilagyi et al., 1993). However, due to the large
variance seen in published studies of tobramycin’s intrinsic PK after IV administration, and the
fact that patients, in which the drug’s inhalation blood level versus time curves were reported,
differed from those used to determine tobramycin’s intrinsic PK, the overall results from metaanalysis did not inspire much confidence in the accuracy with which the drug’s pulmonary
bioavailable fraction in humans could be determined. Likewise, in Chapter III, the rate of the
drug’s absorption from the lung following inhalation, measured using different modeling
techniques was found to produce apparent half lives for pulmonary absorption that ranged from
0.7 through 2.3 hours. Data analysis difficulties were also noted for modeling with some of data
76

to determine absorption rate constants (see legend, Figure III.1), all of which assumed irreversible
absorption from the airways into the systemic circulation. It was only following a review of the
sputum concentration data in patients who had experienced repetitive aerosol dosing, that the
existence of drug binding or sequestration in the lung became a possibility (see Table III.4)

To enhance the understanding of the inhaled drug’s disposition kinetics and mechanisms,
tobramycin’s absorption following airway administration was investigated systematically as a
function of dose and local concentration, using a realistic ex vivo model, the IPRL, as described
by Byron and Niven (1988). Tobramycin’s absorption, from airways to perfusate, expressed as
cumulative fraction of the administered dose absorbed into the perfusate versus time, was seen to
be bi-exponential and dose-dependent, unlike that seen for the marker solutes fluorescein and
mannitol that both showed first-order and dose-independent kinetics (Chapter IV). HPLC-MS
assay techniques were developed with a sufficiently small limit of quantitation (LOQ) to study the
absorption of this chromophore-free aminoglycoside at some of the higher doses studied in the
IPRL (Appendix I). Those assay techniques, when compared with the radiolabel assay (Appendix
III) used for most studies reported in Chapter III produced statistically comparable absorption
profiles (Appendix IV), showing that radiolabel degradation was not significant in the period of
study. Furthermore, the dose-dependent disposition kinetics seen with tobramycin in the IPRL did
not appear to be associated with metabolic degradation, since this class of drugs fails to undergo
metabolism in the body and is excreted unchanged almost entirely by the kidney after IV
administration (Israel et al., 1976; Schentag et al., 1978).
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In this scenario, a kinetic model for tobramycin that incorporated lung tissue binding and/or
sequestration alongside passive absorption was proposed and employed successfully to describe
the aminoglycoside’s disposition in the IPRL following airway administration. Based on the rate
constant data obtained from the kinetic model in the IPRL, tobramycin’s absorption occurred fast
with first-order absorption rate constants (ka = 0.065-0.070 min-1) close to those seen with
fluorescein (0.076 min-1), while a dose-, and concentration-dependent lung tissue binding
mechanism, appeared able to prolong the drug’s presence in the rat lung. This dose-dependent
tissue binding or sequestration appeared to potentially saturable, indicated by the fact in which
forward binding rate constants (k12) decreased as doses (and administered concentrations) were
increased, while backward rate constants (k21) appeared unrelated to dose (see Table IV.2).

This kinetic model was validated using dynamic dialysis experiments involving elution studies
from the whole sliced IPRL preparation. The dynamic dialysis techniques, advocated by Meyer
and Guttman and used subsequently by other groups to study solute-ligand binding (Bottari et al.,
1975; Hashimoto et al., 1984; Hiji et al., 1978; Meyer and Guttman, 1968; 1970; Pedersen et al.,
1977; Sparrow et al., 1982), were modified and used with sliced IPRL tissues in this dissertation
to study the lung tissue binding of tobramycin by directly mimicking the environment in which
the drug was administered to the airways of the preparation. Those studies confirmed that tissue
binding occurred relatively slowly after airway administration and that all three rate constants (for
dialysis, association and dissociation) had a similar order of magnitude (see Scheme IV.3, Table
IV.1). Although the binding sites remained unclear, lung tissues were shown to be clearly
responsible for the antibiotic’s sequestration; this because the constituents of the IPRL airway
lining fluid collected by bronchoalveolar lavage showed no significant binding to tobramycin in
control dialysis studies. While such disposition models appeared to be consistent with observations
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of prolonged sputum concentrations following repeated dosing in the clinic(Gibson et al., 2003;
Govoni et al., 2013; Hubert et al., 2009), the human PK data for this drug were too variable to
discern the magnitude of such effects (Chapetr III). Moreover, it is not known whether
prolongation of tobramycin’s concentrations in the lung due to such binding enable better killing
or whether the antimicrobial effects would be enhanced simply by maximizing the airway
Cmax/MIC ratio for a short duration as discussed by MacArthur et al.(1984).

It was unexpected that tobramycin could be absorbed from the airways of the IPRL faster than
mannitol (ka = 0.018-0.019 min-1), a paracellular (hydrophilic) absorption marker with a much
smaller molecular size (MW 182 Da) than tobramycin (MW 467.5 Da). While the mechanisms
responsible for the drug’s apparent rapid absorption in the IPRL were not studied in this
dissertation, it was noteworthy that tobramycin itself was found to affect airway epithelial integrity
when co-administered at doses as large as 2 and 6 mg to the IPRL airways with mannitol. In this
situation, mannitol’s absorption was accelerated when co-administered with tobramycin and the
viability of the isolated lung preparation appeared to decrease when increasing tobramycin’s
airway dose to the IPRL. The drug’s disruptive effects on airway epithelia however, were
undetectable at a lung dose level of 0.2 mg in rats that was believed to produce similar airway
concentrations to those seen in human patients using TOBI. Based on this reasoning, tobramycin
induced epithelial changes are expected to be minimal at lung doses seen in the clinical treatment
of humans by inhalation. To our knowledge, this is the first report of the effect of aminoglycosides
on airway epithelial integrity even though this class of drugs in some concentrations have been
reported to affect the permeation of vestibular and proximal tubular epithelia, and also cause cell
apoptosis and necrosis due to high local concentrations (see studies of drug-induced oto- and
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nephrotoxicity; Karasawa and Steyger, 2011; Kim et al., 2005; Todd et al., 1994). Whether this
observation has any clinical significance, especially given the fact that the drug is mostly used to
treat lung-infected individuals with CF, who have abnormal airway epithelia in the first place, is
unknown. Nevertheless, these findings may add value to those dealing with formulation
development and dosing strategy designs for other inhaled aminoglycosides.

Overall, by eliminating the variability associated with systemic clearance, and performing a
series of systematic investigations in an ex vivo lung preparation, this dissertation increased our
knowledge of tobramycin disposition following airway administration. As a polycation at
physiological pH (Szilagyi et al., 1993), the aminoglycoside showed a unique ability to bind or
sequester in the lung that appeared to prolong the drug’s local presence and, thereby, extend its
anti-infective effects following inhalation. The drug’s tissue binding properties may account, at
least in part, for the apparent success of tobramycin inhalation therapy seen in clinical practice.
The findings in this dissertation may also assist with development of future research in this
important therapeutic area of antibiotic therapies for pulmonary administration, given that the
models developed in Chapter IV enable kinetic interpretation of the clinical studies in humans in
which repetitive dosing showed, albeit inconclusively, accumulation and prolonged antibiotic
durations following topical delivery. Further exploration of the mechanisms responsible for
aminoglycosides’ lung sequestration with other aminoglycosides, may enable future design and
development of drugs for pulmonary administration with prolonged lung retention.

80

Appendices

81

Appendix I
HPLC MASS SPECTROMETRIC ANALYSIS OF TOBRAMYCIN IN PERFUSATE

AI.a Introduction
In this appendix, the development and validation of an HPLC-MS method suitable for
tobramycin assay in perfusate in the IPRL is described. The method overcomes the adsorption
problems of aminoglycosides on glass and other surfaces (Josephson et al., 1979) and employs
solid phase extraction followed by reverse phase HPLC with trifluoroacetic acid (TFA) as an ionpairing agent. Mass detection using a single quadrupole mass spectrometer in positive detection
mode with electrospray ionization (ESI) confers sensitivity and specificity.
AI.b Methods and materials
Chemicals and materials
Tobramycin was purchased from Sigma-Aldrich (MO, USA), acetonitrile (CAN; HPLC-grade),
methanol (HPLC-grade), buffer salts (KCl, KH2PO4, CaCl2, MgSO4, NaHCO3) and dextrose were
supplied by Fisher Scientific (Pittsburgh, PA). Bovine serum albumin (BSA), trifluoroacetic acid
(TFA) and heptafluorobutyric acid (HFBA) were purchased from Sigma-Aldrich (St. Louis, MO).
Bond-ELUT-C18 cartridges (100mg, 1 mL) used for solid phase extraction (SPE) were obtained
from Varian Inc. (Walnut Creek, CA). Pipette tips (200uL and 1000uL) and centrifuge tubes (2mL)
were made of polypropylene (PPE) and purchased from Fisher Scientific. Small volume HPLC
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vial inserts (250uL, PPE) were obtained from MicroSolv (Eatontown, NJ). The perfusate (K4) is
the modified Krebs-Henseleit solution(KHS) with 4% bovine serum albumin (BSA) (w/v)
containing 4.7mM KCl, 143.3mM NaCl, 1.2mM MgSO4, 2.52mM CaCl2, 1.2mM KH2PO4, 5mM
glucose, prepared as described in Chapter IV. The perfusate pH was adjusted to 7.4 at room
temperature; solutions were stored at 4°C and used within 48 hours.

HPLC-MS method development

Chromatographic and mass spectrometric conditions. Alliance 2695 system (Waters,
Milford, MA) was used for chromatographic separation by a Hypersil Gold C18 column
(150×4.6mm, 3µm; Thermo Scientific, Waltham, MA). Isocratic elution at a flow rate of 0.3
mL/min was used with the mobile phase consisted of acetonitrile (ACN): 0.1% v/v TFA water
solution (volume fraction ratio, 30:70), where TFA functioned as an ion pairing agent to
increase tobramycin’s retention on the column. Chromatographic performance (peak shape and
symmetry) using mobile phase containing different TFA concentrations was assessed to
determine the appropriate TFA concentration in the mobile phase for the analysis. The injection
volume was hold at 10 μL. The mass spectrometry detector was a ZMD 4000 (Waters
Corporation, Milford, MA) equipped with an electrospray interface in positive ionization mode.
The parameters were set as: capillary voltage 3.78 kV; cone voltage 20 V; extractor 6 V; Rf
Lens 0.1 V; source block temp 130 °C; desolvation temp 350 °C; nitrogen desolvation flow 600
L/min. Tobramycin was determined by single ion monitoring (SIM) for the molecular ion
[M+H]+ at m/z 468.61. Masslynx NT 3.5 (Waters) was used for the HPLC-MS system control
and data processing.
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Calibration standards and quality controls. The stock standard solution of tobramycin at 1
mg/mL was prepared in water and further diluted with ACN –H2O (80:20) containing 0.4% TFA,
to obtain the standard solutions at concentrations of 50, 20, 10, 5, 2, 1, and 0.5 µg/mL. These
standard solutions were then diluted by 10 fold with blank perfusate to obtain perfusate calibration
standards at concentrations of 5, 2, 1, 0.5, 0.2, 0.1, 0.05 µg/mL. Quality control samples in
perfusate at the lowest limit of quantification (LLOQ) and low, medium and high concentration
levels were prepared in triplicate in the same way as these calibration standards.
Solid phase extraction and sample pretreatment. Tobramycin perfusate samples, calibration
standards in perfusate and quality control samples were pretreated with 5% v/v HFBA water
solution in a volume ratio of 1:1 followed by centrifugation at 14,000 rpm for 10 minutes at 4 °C
(Eppendorf, Centrifuge 5804R, Hamburg, Germany) to enable protein precipitation and
simultaneously, ion pairing. A volume of 1 mL supernatant solution was then taken from each
sample and solid phase extraction was performed for sample clean-up with Bond-ELUT-C18
cartridges (100mg, 1 mL) using the following procedure:
Conditioning: 1 mL methanol and 1ml 5 mM HFBA water solution;
Loading: 1 mL supernatant solution prepared above;
Washing: 1 mL 5 mM HFBA water solution (×2);
Eluting: 1 mL ACN: H2O 90:10 (containing 1% v/v TFA).
Eluent solutions collected in polypropylene (PPE) centrifuge tubes were evaporated to dryness
at 40 °C under vacuum and reconstituted with the dilution solvent. These reconstituted solutions
were transferred to 250 µL polypropylene (PPE) inserts and aliquots of 10 µL were injected onto
the HPLC column.
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The adsorption of tobramycin onto the surfaces of glass HPLC vials and polypropylene inserts
were assessed using tobramycin standard solutions prepared in different dilution solvents. The
dilution solvent was selected from H2O, ACN –H2O (80:20), ACN –H2O (30:70) containing 0.1%
or 0.4% v/v TFA, and ACN –H2O(80:20) containing 0.1% or 0.4% v/v TFA, based on the results
of screening experiments designed to assess peak shape, injection reproducibility and adsorption
losses. The storage and transfer containers used in sample pretreatment were all made of
polypropylene in order to avoid surface adsorption losses onto glass that have previously been
reported with aminoglycosides (Josephson et al., 1979).

Validation Procedures.
Calibration. Perfusate calibration standards after solid phase extraction were analyzed by
HPLC-MS. Tobramycin peak areas from the corresponding chromatograms versus nominal
concentrations were fitted using a Masslynx regression method based on a best-fit procedure
(Figure AI.3). Deviation of the calculated concentration of each calibrator from the nominal
one, expressed as the percentage of the nominal concentration (% Dev), should be within ±15%
except at the LLOQ level in which a deviation of ±20% was permitted.
Accuracy, precision and extraction recovery. Accuracy was defined as the ratio, expressed
as a percentage, of the experimentally determined concentration to the spiked drug
concentration in each quality control sample. Precision was expressed by coefficient of
variation, CV%, of the experimental determined concentrations of each quality control sample
injected in 3 separate runs within a day (= SD / Mean× 100%, where “Mean” is the mean of
the experimentally determined concentrations from 3 separate runs and SD is the standard
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deviation of the “Mean”). The efficiency and reproducibility of solid phase extraction was
evaluated by extraction recovery rate, expressed as percentages, calculated by eq. AI.1:
100%

Extraction rate =
where

eq. AI.1

refers to the peak area obtained from each extracted quality control,
is the average peak area of tobramycin obtained from the standard solutions

prepared in duplicate with the dilution solvent at the same nominal concentration as that in the
quality control sample.

Matrix effects.
Matrix effects, defined as the impact of the perfusate components and endogenous metabolic
byproducts derived from the dying IPRL tissue during recirculation through the rat lung
vasculature on the assay’s accuracy, were assessed for “IPRL-free” blank perfusate and 4 batches
of IPRL control perfuste, in which two batches of IPRL control perfusate (Batch 1 and 2) were
obtained by circulating purfusate in the IPRL vasculature for 0.5 hour using two different rat lungs,
and another two batches of control perfusate (Batch 3 and 4) were collected from the re-circulated
perfusate using a third rat lung after 0.5 hour (Batch 3) and 2 hours (Batch 4). These four batches
of IPRL control perfusate as well as “IPRL-free” blank perfusate sample were pretreated by solid
phase extraction, and reconstituted with the dilution solvent. Matrix effects were evaluated using
both a post-column infusion and a post-extraction addition method. In the post-column infusion
method, tobramycin standard solution at 1000 ng/mL was infused into the MS detector by a syringe
pump at a flow rate of 5 µL/min, while the mobile phase was also pumped to the MS detector at a
flow rate of 0.3 mL/min operated by a Tee-valve device. Aliquots of 10 µL of reconstituted
solutions of these perfusate extracts were injected onto the column when performing post-column
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infusion. The chromatograms were collected based on single ion monitoring of m/z 468.61; a
negative peak was expected to indicate signal suppression while a positive peak was expected
show signal enhancement due to the components in the matrices. For the post-extraction
addition method, only the batch of perfusate which was recirculated in IPRL for 2 hours and
the “IPRL-free” blank perfusate, were used for this purpose. These perfusate batches were
sampled and extracted by solid phase extraction; after evaporating to dryness, a volume of 50
μL standard solutions in dilution solvent at the concentrations of 50, 10, 1 μg/mL were added
to the dried 2ml centrifuge tubes containing perfusate residues and diluted by 450 μL dilution
solvent to produce tobramycin solutions at concentrations at 5000 (high), 1000 (medium), and
100 (low) ng/ml (two replicates at each concentration for each batch of perfusate). The
corresponding standard solutions at these concentrations were prepared similarly in duplicate
but using 2 ml clean centrifuge tubes, as reference solutions. Matrix effects were evaluated by %
deviation (% dev.) of mean peak area obtained from the injections of those solutions prepared
with perfusate matrices

, from that in the reference solutions,

,

calculated by:
100%

% dev. =

eq. AI.2

Adsorption test on the IPRL apparatus.
Since the IPRL apparatus included glassware, tobramycin adsorption onto the complete IPRL
apparatus was assessed for perfusate samples at low concentration (100 ng/mL) in three replicates
to evaluate the applicability of the IPRL standard apparatus for studies of tobramycin disposition.
Briefly, 200 mL of blank perfusate was circulating in the IPRL apparatus at 37 ˚C simulating the
real experimental condition except the absence of an isolated rat lung. An aliquot of 0.1 mL
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tobramycin solution in water at 200 µg/mL was added the perfusate, and sampling of perfusate
from the IPRL system was begun at 5 minutes after adding the tobramycin solution and followed
at 30, 60, 90 and 120 minutes. The experiment was repeated three times and the profiles of
tobramycin concentration versus time were plotted and the adsorption of tobramycin onto the IPRL
apparatus in the presence of perfusate was evaluated as a function of time by comparing
tobramycin concentration at each sample time point with the spiked tobramycin concentration of
100 ng/mL, using mixed-effects repeated-measures ANOVA with p value 0.05 by JMP 8.0, to
assess whether there was statistically significant drug loss during circulation of this tobramycin
perfusate solution through the IPRL apparatus system for 2 hours.

AI.c Results and discussion

Chromatograms and mass spectrums
Volatile ion pairing agent TFA was employed in this study to achieve analyte retention in the
C18 column. The retention time of tobramycin was increased and peak shape was improved by
increasing the concentration of TFA in the mobile phase as shown in Figure AI.1. A mobile phase
consisting ACN-0.1% v/v TFA (30:70) was chosen because of the improved chromatographic
performance that resulted from this condition in which the analyte showed moderate retention at
5.4 min and a symmetric peak shape
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Mobile Phase ACN ‐0.1% v/v TFA (30:70)

Mobile Phase ACN‐ 0.05% v/v TFA (30:70)

Mobile Phase ACN ‐ 0.025% v/v TFA (30:70)

Figure AI.1 Effects of TFA concentration in mobile phase on chromatography.
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+

[M+H]

Figure AI.2 Mass spectrum of tobramycin

The mass spectrum of tobramycin is shown in Figure AI.2 in which peaks corresponding to the
molecular ions [M+H]+ at m/z 468.65 was observed in addition to the daughter ions at m/z 324.46,
and 163.11, resulting from cleavage of glycosidic bonds and the subsequent loss of the aminosugar
rings (Li et al., 2009). The molecular ion [M+H]+ at m/z 468.65 was chosen for single ion
monitoring in this method for its greatest abundance and specificity.
Solid phase extraction and sample pretreatment.
The perfusate matrix is the modified Krebs-Henseleit buffer containing 4% (w/v) bovine serum
(BSA). The large amount of buffer salts and albumin in the perfusate made direct injections of
samples onto the LC column followed by mass spectrometric detection impossible. Therefore,
solid phase extraction was employed for the sample pretreatment after a deproteination procedure
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with 5% v/v HFBA, before loading to C18 SPE cartridges. With these sample preparation
procedures, a complete extraction was achieved with good reproducibility (see Accuracy, precision
and extraction recovery in Table AI.3). Since the extraction recovery appeared to be complete and
reproducible, the use of an internal standard seemed not to be necessary. Therefore, the
quantification was based on the external standard method and validated as suitable for the assay
of tobramycin in perfusate.
Although aminoglycosides’ adsorption on container surfaces has been known and reported
(Josephson et al., 1979), very few published bioanalytical methods addressed the problem. For
tobramycin solutions in solvents such as water, water/acetonitrile mixture, or with mobile phase
modifier agents such as TFA, there are no specific studies regarding aminoglycosides adsorption
from solution on container surfaces. In this study, tobramycin adsorption onto the surfaces of 2
mL glass HPLC vials versus 250 μL polypropylene (PPE) inserts was evaluated when tobramycin
standard solutions were prepared in different vehicles such as water, ACN-H20, ACN-H20
containing TFA. As for the storage in 2mL HPLC glass vials, the detected concentrations of
tobramycin standard solutions in water or ACN–H2O (80:20) at concentration of 1000 ng/mL were
observed to decrease 44.3% after 2 hours and the peak of tobramycin was hardly detected after 9
hours, while 1000 ng/mL tobramycin in ACN –H2O (80:20) containing 0.4% v/v TFA showed no
change of the detectable concentration (data not shown). While ACN –H2O (80:20) containing 0.4%
v/v TFA as dilution solvent appeared to prevent tobramycin adsorption, the tobramycin peak for
100 ng/mL tobramycin standards prepared with this solvent was split in the tail or showed a
shoulder when stored in glass vials. Interestingly, tobramycin peak was symmetric and absent of
tail or peak shoulder for the same solution when a PPE insert was used for HPLC injections.
Moreover, PPE containers could effectively reduce the drug’s adsorption onto surfaces. However,
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when tobramycin standards were stored in PPE inserts, the detected concentrations of 100 ng/mL
decreased by 69.9 and 74.6 ng/mL after 9 hours in water and ACN–H2O (80:20), respectively.
Using ACN–H2O (80:20) containing 0.4% v/v TFA as the solvent, the detectable concentrations
of these standards at 100, 500 and 1000 ng/mL showed no decrease after 9 hours (see Table AI.1).
In conclusion, PPE inserts used with a dilution solvent containing 0.4% TFA removed the
adsorption problem. Furthermore, assay precision was also improved when this dilution solvent
was employed (Table AI.2).

Table AI.1 Detectable concentrations of tobramycin standard solutions prepared in ACN–H2O
(80:20) containing 0.4% v/v TFA at 100, 500 and 1000 ng/mL stored in PPE inserts for 9 h at room
temperature before injection.

After 9 h storage in PPE inserts
Nominal Conc.(ng/ml)
(Mean Conc.±SD)
1000
500
100

1003.9±91.5
491.3±22.4
104.9±6.9

Table AI.2 Precision of repeated injection of 100 ng/mL tobramycin standard prepared in
different dilution solvents.
Dilution solvent
ACN-H20 (30:70) 0.1% TFA
ACN-H20 (30:70) 0.4% TFA
ACN-H20 (80:20) 0.1% TFA
ACN-H20 (80:20) 0.4% TFA

5 runs Precision
(CV%)
14.3%
19.0%
13.1%
5.3%

Validation
Calibration Figure AI.3 shows the calibration curve for tobramycin standards in perfusate (7
concentration levels, 50-5000 ng/mL) using an external standard. The peak area of tobramycin
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versus the nominal concentrations in the standards was best fitted with a quadratic equation
(software: Masslynx NT 3.5) to provide the solid curve with correlation coefficient equal to 0.995.
The % deviation of the determined concentrations for each calibrator to the nominal ones were all
within 11% as shown in Figure AI.3.

Compound name: Tobi
Coefficient of Determination: 0.995202
Calibration curve: 0.000715121 * x^2 + 6.96625 * x + -59.9471
Response type: External Std, Area
Curve type: 2nd Order, Origin: Exclude, Weighting: 1/x^2, Axis trans: None

Nominal Conc
(ng/mL)

%Dev

5000
2000
1000
500
200
100
50

-3.2
10.5
4.5
-1.5
-14
-2.4
4.4

52649
Response
-60

ng/ml
0

500

1000 1500 2000 2500 3000 3500 4000 4500

Figure AI.3 Calibration curve of tobramycin standards in perfusate

Accuracy, precision and extraction recovery
Accuracy, precision and extraction recovery of solid phase extraction for quality controls of
tobramycin in perfusate are presented in Table AI.3. Accuracies ranged from 89.9 to 102.3%
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and precision, expressed as CV%, were within 5.5% for tobramycin quality control standards at
LLOQ, low, medium and high concentration levels. The extraction recovery rates of solid phase
extraction for quality controls at low, medium and high concentrations were 101.6%, 103.7% and
97.5%, respectively. LLOQ was set to 50 ng/mL, according to the FDA guidance for Bioanalytical
Method Validation that required accuracy at this concentration level ranging from 80-120% of
nominal

and

precision

(CV%)

of

repeated

measurements

less

than

20%

(http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf).

Table AI.3 Accuracy, precision and extraction recovery
Nominal
Conc.
(ng/mL)
5000
1000
100
50

Accuracy (%)
3 replicates
Mean
SD
93.9
3.0
102.3
4.1
89.9
3.8
101.8
2.8

Precision
3 replicates
CV%
4.0
3.8
5.5
2.6

Recovery (%)
3 replicates
Mean
SD
101.6
4.3
103.7
4.6
97.5
4.5

Matrix effects
Reconstituted solutions of “drug-free” perfusate residues were injected to the HPLC column as
described in the post-column infusion method. The chromatograms are shown in Figure AI.4. Ion
suppression occurred at a retention time of 4.5 and 5.7 min, while ion enhancement occurred at
6.4 min for all the injections of these “drug-free” perfusate samples (Figure AI.4). These effects
did not complicate tobramycin determinations (retention time = 5.4 min, Figure AI.1). The
chromatogram of blank perfuate showed no obvious difference from those from the 4 batches of
IPRL control perfusate (See Figure AI.4). Likewise, there was no detectable difference in the
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chromatograms when the perfusate was recirculated in the pulmonary vasculature of the IPRL for
either 0.5 or 2 h (Figure AI.4) and also no detectable difference for the IPRL control perfusate
obtained from different rats (data not shown). Although the peak of tobramycin (retention time at
5.4 min) could be resolved even with matrix effects, further confirmation was performed using the
post-extraction addition method to assess whether the residuals (after solid phase exaction) of
perfusate components and endogenous metabolic byproducts from the dying tissue during
recirculation in the rat lung vasculature affected the assay’s accuracy. Table AI.4 shows %
deviation (% dev.) of mean peak area obtained from the injections of tobramycin standards
from that in the reference solutions (the

prepared with perfusate matrix

standard solution prepared in the absence of perfusate matrix),

. In these results, the

values of % dev. for low (100 ng/mL), medium (100 ng/mL) and high (5000 ng/mL) concentrations
were within 15%, indicating that the matrix components in the blank perfusate and IPRL control
perfusate re-circulating in the isolated rat lung vasculature did not change the assay’s accuracy for
spiked standards prepared in the presence of extracted perfusate. These results also implied that
this solid phase extraction technique could effectively remove interfering matrix components other
than the analyte.

95

Blank perfusate

Batch 3: Control perfusate recirculated in IPRL for 0.5 h

Batch 4: Control perfusate recirculated in IPRL for 2 h

Figure AI.4 Chromatograms of perfusate with post-column infusion of 1 µg/mL
standard solution

Table AI.4 % dev. of mean peak area of tobramycin in perfusate matrices (extracted) from that
in the reference solutions (standard solutions prepared in the absence of perfusate matrices)
Nominal
Conc.
(ng/mL)
5000
1000
500
100

for IPRL control perfusate that
recirculated in the pulmonary
vasculature of the rat lung for 2h
% dev.
-2.7
5.7
-6.5
8.3

for “IPRL-free” blank
perfusate
% dev.
2.1
5.7
7.1
13.8

Adsorption tests in the IPRL apparatus

Circulating tobramycin perfusate solution in the IPRL apparatus in the absence of rat lungs at
37°C for 2 hours failed to show a concentration decrease due to adsorption loss to the apparatus.
The determined concentrations at each sampling time showed no significant changes from the
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nominal concentration of 100 ng/mL over 2 hours using mixed-effects repeated-measures ANOVA
(p value > 0.05; Figure AI.5). It is possible that the high content of BSA in the perfusate effectively
prevented the drug’s adsorptive losses onto the apparatus in this case.

Figure AI.5 Adsorption test of tobramycin on the IPRL apparatus
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Appendix II
RADIOACTIVE [3H]TOBRAMYCIN SPECIFICATIONS

This shows a copy of certificate of analysis and product data sheet with analytical
specifications provided by Moravek Biochemicals, Inc. Brea, CA. The claimed radiochemical
purity of the tritiated drug was 98.5% on Dec. 14, 2011.
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Appendix III
RADIOACTIVE [3H]TOBRAMYCIN ASSAY IN PERFUSATE

Perfusate samples containing [3H]tobramycin obtained from IPRL experiments were assayed
in a Liquid Scintillation Analyzer (LSA) (Tri-Carb 2800-TR, PerkinElmer) directly or after
appropriate dilution in blank perfusate; the counts were corrected by subtracting the background
due to blank perfusate. Tobramycin concentrations in perfusate samples for each IPRL experiment
were calculated based on the comparison of radioactive content between perfusate samples and the
dosing solution used in the same IPRL study. For each IPRL experiment, the dosing solution
prepared with trace amount of [3H]tobramycin was diluted 2000 fold by blank perfusate to prepare
the control solution for the assay. The total radioactivity in samples, expressed as DPMs
(disintegrations per minute), in 1 mL of each solution was determined by LSA, after mixing with
5 mL of scintillation cocktail (Ecoscint XR, National Diagnostics, Atlanta, GA) followed by 4
hours of storage in the dark at room temperature prior to analysis. Control solutions were prepared
in duplicate. Corrected DPMs of perfusate samples were used for calculation of tobramycin
concentration, Csample, according to the formula:
Csample = DPMsample / mean DPMcontrol ×

eq. AIII.1

where DPMsample and mean DPMcontrol are the corrected radioactive counts from samples and
refers to the nominal concentration of each

duplicate controls, respectively, while

control solution (0.5‰ of solute concentration in dosing solution).
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A comparison of the HPLC-MS and radioactive analysis methods is shown for tobramycin
absorption in Appendix IV. Notably, such a comparison could only be performed at a relatively
high dose (2mg) that produced perfusate concentrations enabling accurate assay by HPLC-MS.
Radioactive methods were needed for lower doses.
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Appendix IV
COMPARISON OF IPRL ABSORPTION DATA FOR TOBRAMYCIN:
RADIOACTIVITY ASSAY VERSUS HPLC-MS

AIV.a Introduction
The HPLC-MS method described in Appendix I successfully assayed tobramycin perfusate
samples at concentrations no less than 50 ng/mL. Nevertheless, the detection sensitivity was not
sufficient for the studies of tobramycin absorption in the IPRL at doses lower than 0.2 mg, in which
tobramycin concentrations in the re-circulating perfusate in most cases were < 50 ng/mL if sample
time less than 10 minutes following administration. In order to study tobramycin’s disposition
kinetics for a wide range of airway doses (from 0.002 to 2 mg) in the IPRL therefore, a radioactivity
assay using liquid scintillation counting (described in Appendix III) was employed. This appendix
describes a comparison of the cumulative fraction of administered dose absorbed into the perfusate,
Fp, as a function of time, from two parallel groups of IPRL absorption experiments in which the
surgery, establishment and maintenance of the IPRL, and the dosing technique and perfusate
sampling, were all fixed except perfusate samples were assayed either by HPLC-MS or
radioactivity. The Appendix also describes the general methods used to calculate Fp from the
concentration data that was collected in each experiment.

AIV.b Methods
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IPRL absorption studies using either tritium-labeled tobramycin or unlabeled tobramycin were
performed according to Chapter IV. For six separate IPRL absorption experiments using
tobramycin dosing solution at 20 mg/mL containing 18μCi/mL [3H]tobramycin, perfusate samples
were analyzed by radioactivity assay as described in Appendix III. For 4 separate IPRL absorption
experiments using unlabeled tobramycin solutions at 20 mg/mL, perfusate samples were analyzed
using the HPLC-MS method described in Appendix I. For each IPRL experiment, tobramycin
concentrations in the re-circulating perfusate at each sampling time,

, were determined

to calculate the cumulative absorbed amount from airway to the perfusate, and the cumulative
fraction of administered dose absorbed into the perfusate (Fp) by the equation:
∑

where

and

eq. AIV. 1

are the drug concentration in the circulated perfusate and the total

volume of the re-circulating perfusate in the IPRL system at time t, respectively;
drug concentration in each perfuate sample, and

is the

is the volume of that perfusate sample

withdrawn at each sampling time (=1mL); ∑

is the total amount of drug in

perfuate samples taken before time t. Notably, no blank perfusate was added to replace perfusate
after each sample was withdrawn in IPRL absorption experiments. After the last time point, the
recirculating perfusate was collected and measured, to determine

and used to calculate

.

The values of Fp at each sampling time were compared statistically between the two assay methods
using multiple t tests and a p value 0.05.

AIV.c Results and discussion
For each IPRL experiment, sampling time,

,

, cumulative amount of dose absorbed

into perfusate from the airway, and Fp are tabulated in Table AIV.1 (using the radioactivity assay)
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and Table AIV.2 (using the HPLC-MS method). The mean±SD of Fp values at each sampling time
determined by the HPLC-MS method and the radioactivity assay are shown in Fig. AIV.1. For the
IPRL experiments using the HPLC-MS method, there were not sufficient data at 1, 105 and 120
minutes to perform a statistical comparison. The comparison of Fp therefore, was performed at 3,
5, 10, 20, 30, 40, 50, 60, 75, 90 minutes for the two parallel groups of IPRL absorption experiments.
There was no statistical difference of the values Fp between the two parallel groups at any of these
sampling times (t-test, p value >0.5), indicating that the IPRL absorption results were consistent
when the two different assay techniques were employed. The results implied that assaying
perfusate samples based on radioactivity content by LSA were accurate and specific for
tobramycin since the IPRL absorption data determined by this technique were comparable with
those determined by the HPLC-MS method in which tobramycin was quantitated using single ion
monitoring of tobramycin’s molecular ion [M+1]+.
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Figure AIV.1 Mean cumulative fraction of administered tobramycin dose absorbed into perfusate
versus time determined by HPLC-MS or the radioactivity assay (nominal doses are 2 mg)
Table AIV.1 IPRL absorption data of tobramycin determined by radioactivity assay (6 IPRL
preparations)
Rat Lung #1
Administered dose
Sampling time
(min)
1
3
5
10
15
20
30

[3H]tobramycin
2027.5 μg
(µg/mL)
0.632
1.559
2.316
2.980
3.490
3.608
4.443

(mL)
200
199
198
197
196
195
194
114

Cumulative
absorbed amount
(μg)
126.44
310.93
460.82
591.54
691.52
714.58
876.62

Fp
0.062
0.153
0.227
0.292
0.341
0.352
0.432

40
50
60
75
90
105
120

Rat Lung # 2

Sampling time
(min)
1
3
5
10
15
20
30
40
50
60
80
90
105
120
Rat Lung # 3

Sampling time
(min)
1
3
5
10
15
20

4.609
4.640
5.204
5.705
5.895
6.338
6.632

193
192
191
190
189
188
187

[3H]tobramycin
Administered dose
(µg/mL)
0.765
1.108
1.409
2.029
2.420
2.953
3.351
3.865
4.069
4.647
4.998
5.384
5.881
6.153

(µg/mL)
1.033
1.598
2.106
3.326
4.026
4.549

Cumulative
absorbed amount
(μg)
162.95
235.61
299.24
429.43
511.02
621.86
704.30
810.32
852.03
970.02
1041.27
1119.19
1219.18
1273.47

Fp
0.071
0.103
0.131
0.188
0.223
0.272
0.308
0.354
0.372
0.424
0.455
0.489
0.533
0.556

2255.2 μg

(mL)
213
212
211
210
209
208
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0.448
0.451
0.504
0.551
0.569
0.610
0.637

2289.4 μg
(mL)
213
212
211
210
209
208
207
206
205
204
203
202
201
200

[3H]tobramycin
Administered dose

908.66
914.60
1022.20
1117.42
1153.33
1236.66
1291.67

Cumulative
absorbed amount
(μg)
219.93
339.88
446.95
703.21
849.58
958.19

Fp
0.098
0.151
0.198
0.312
0.377
0.425

30
40
50
60
75
90
105
120

Rat Lung # 4

Sampling time
(min)
1
3
5
10
15
20
30
40
50
60
75
90
120

Rat Lung # 5
Administered dose
Sampling time
(min)
1
3
5
10
15

5.152
5.036
5.359
5.972
6.682
6.926
7.236
6.325

207
206
205
204
203
202
201
200

[3H]tobramycin
Administered dose

0.480
0.521
0.553
0.615
0.618
0.640
0.668
0.727

Cumulative
absorbed amount
(μg)
144.35
293.20
389.95
553.31
653.94
698.65
791.84
845.77
895.05
939.00
889.74
1029.23
1046.92

Fp
0.080
0.163
0.217
0.307
0.363
0.388
0.440
0.470
0.497
0.521
0.494
0.572
0.581

1800.7 μg

(mL)
204
203
202
201
200
199
198
197
196
195
194
193
192

(µg/mL)
0.708
1.441
1.920
2.733
3.236
3.460
3.931
4.205
4.456
4.682
4.428
5.150
5.243

1083.12
1174.48
1247.49
1385.87
1394.54
1443.89
1506.28
1640.36

[3H]tobramycin
1953.22 μg

(µg/mL)
0.885
1.343
1.665
2.276
2.844

(mL)
203
202
201
200
199
116

Cumulative
absorbed amount
(μg)
179.69
272.14
336.84
459.12
572.26

Fp
0.092
0.139
0.172
0.235
0.293

20
30
40
50
60
75
90
105
120

Rat Lung # 6
Administered dose
Sampling time
(min)
1
3
5
10
15
20
30
40
50
60
75
90
105
120

3.008
3.524
3.964
4.168
4.549
4.831
5.076
5.329
5.648

198
197
196
195
194
193
192
191
190

604.74
706.46
792.58
832.60
906.52
961.14
1008.27
1056.71
1117.61

0.310
0.362
0.406
0.426
0.464
0.492
0.516
0.541
0.572

Cumulative
absorbed amount
(μg)
197.36
442.56
586.72
783.47
854.93
906.82
1028.52
1061.15
1062.85
1059.40
1084.06
1174.89
1217.67
1232.62

Fp
0.102
0.230
0.305
0.407
0.444
0.471
0.534
0.551
0.552
0.550
0.563
0.610
0.632
0.640

[3H]tobramycin
1926.2 μg

(mL)
202
201
200
199
198
197
196
195
194
193
192
191
190
189

(µg/mL)
0.977
2.197
2.918
3.906
4.267
4.531
5.152
5.319
5.328
5.310
5.438
5.914
6.139
6.218
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Table AIV.2 IPRL absorption data of tobramycin determined by HPLC-MS assay (4 IPRL
preparations)

Rat Lung #7
Administered dose

unlabeled tobramycin
1791.5 μg

Sampling time
(min)

(µg/mL)

(mL)

Cumulative
absorbed amount
(μg)

3
5
10
15
20
30
40
50
60
75
90

1.908
2.456
3.032
3.271
3.525
3.828
4.023
4.448
4.489
4.721
4.702

204
203
202
201
200
199
198
197
196
195
194

389.25
500.52
616.87
664.84
715.62
775.94
814.59
898.26
906.24
951.52
947.98

0.217
0.279
0.344
0.371
0.399
0.433
0.455
0.501
0.506
0.531
0.529

Cumulative
absorbed amount
(μg)
223.66
370.04
452.60
536.37
607.06
633.96
697.79
688.77
741.22
760.31
853.43
853.78

Fp
0.123
0.204
0.249
0.296
0.335
0.349
0.385
0.380
0.409
0.419
0.470
0.471

Rat Lung #8
Administered dose
Sampling time
(min)
1
3
5
10
15
20
30
40
50
60
75
90

Fp

unlabeled tobramycin
1814.1 μg

(mL)
200
199
198
197
196
195
194
193
192
191
190
189

(µg/mL)
1.118
1.854
2.271
2.696
3.057
3.195
3.524
3.477
3.750
3.850
4.340
4.342
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Rat Lung # 9
Administered dose
Sampling time
(min)
1
3
5
10
15
20
30
40
54
60
75
90

Rat Lung # 10

unlabeled tobramycin
1799.2 μg

(mL)
200
199
198
197
196
195
194
193
192
191
190
189

(µg/mL)
0.452
1.066
1.534
2.167
2.710
3.057
3.726
4.211
4.392
4.646
5.033
5.299

Fp
0.050
0.119
0.170
0.240
0.299
0.336
0.407
0.458
0.476
0.501
0.539
0.565

unlabeled tobramycin

Administered dose
Sampling time
(min)
3
5
10
15
20
30
40
50
60
75
90
105
120

Cumulative
absorbed amount
(μg)
90.49
213.23
306.28
431.76
537.47
604.14
732.36
823.71
855.60
900.54
970.36
1016.43

1834.7 μg

(µg/mL)
0.209
0.365
0.852
1.492
1.699
2.385
2.888
3.396
3.939
4.502
5.047
5.238
5.491

(mL)
203
202
201
200
199
198
197
196
195
194
193
192
191
119

Cumulative
absorbed amount
(μg)
42.44
73.84
171.79
299.83
341.00
476.87
575.97
675.51
781.42
890.52
995.86
1032.54
1080.73

Fp
0.023
0.040
0.094
0.163
0.186
0.260
0.314
0.368
0.426
0.485
0.543
0.563
0.589
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